Version history
4 versions on record. Newest first; the live version sits at the top with a live indicator.
- Live4/26/2026, 2:20:50 PM
7f721ac60917Content snapshot
{ "content_md": "# Microglial Senescence Pathway in Neurodegeneration\n\n## Overview\n\nMicroglial senescence represents a critical mechanism linking aging to neurodegenerative diseases. As microglia age, they undergo cellular senescence, losing their protective functions and adopting a pro-inflammatory, toxic phenotype that accelerates neuronal dysfunction and death. This pathway page details the molecular cascade from microglial senescence to neurodegeneration in Alzheimer's Disease (AD) and Parkinson's Disease (PD). [@micrornas2021]\n\n## Mechanism\n\n### Mermaid.js Pathway Diagram\n\n```mermaid\nflowchart TD\n A[\"Aging / DNA Damage / Telomere Shortening\"] --> B[\"Microglial Senescence Initiation\"]\n B --> C[\"p53/p21 Activation\"]\n B --> D[\"p16-INK4a Accumulation\"]\n C --> E[\"Cell Cycle Arrest\"]\n D --> E\n E --> F[\"SASP Secretion (IL-1beta, IL-6, TNF-alpha)\"]\n F --> G[\"Chronic Neuroinflammation\"]\n F --> H[\"Impaired Phagocytosis\"]\n G --> I[\"Synaptic Loss\"]\n H --> J[\"Amyloid-beta / alpha-Syn Accumulation\"]\n I --> K[\"Cognitive Decline\"]\n J --> K\n K --> L[\"Neurodegeneration (AD/PD)\"]\n```\n\n## Molecular Details\n\n### Senescence Initiation\n\n**DNA Damage Accumulation**: Over time, microglia accumulate DNA damage from oxidative stress, mitochondrial dysfunction, and environmental exposures. The DNA damage response (DDR) pathways become chronically activated, eventually leading to cellular senescence. [@s2020]\n\n**Telomere Shortening**: Microglial telomeres shorten with each cell division and oxidative stress exposure. Critically short telomeres trigger DNA damage responses that activate senescence pathways. [@pet2021]\n\n**Mitochondrial Dysfunction**: Aged microglia exhibit impaired mitochondrial function, leading to increased reactive oxygen species (ROS) production, reduced ATP levels, and further DNA damage—a vicious cycle that accelerates senescence. [@microglial2021a]\n\n### Senescence Effectors\n\n**p53/p21 Pathway**: The tumor suppressor p53 and its downstream effector p21<sup>CIP1</sup> are key mediators of cellular senescence. Chronic activation leads to irreversible cell cycle arrest. [@metabolic2020]\n\n**p16<sup>INK4a</sup>**: This cyclin-dependent kinase inhibitor accumulates in senescent microglia and maintains the senescent state by preventing cell cycle progression. [@nad2021]\n\n### Senescence-Associated Secretory Phenotype (SASP)\n\nThe SASP is a hallmark of senescent cells, characterized by the secretion of: [@epigenetic2020]\n\n- **Pro-inflammatory cytokines**: IL-1β, IL-6, TNF-α\n- **Chemokines**: CXCL8, MCP-1 (CCL2), CCL5\n- **Growth factors**: GM-CSF, G-CSF\n- **Proteases**: MMP-3, MMP-9\n- **ROS and RNS**: Superoxide, nitric oxide\n\n## Disease-Specific Mechanisms\n\n### Alzheimer's Disease\n\nIn AD, microglial senescence contributes to: [@histone2021]\n- Reduced clearance of [amyloid-beta](/proteins/amyloid-beta) plaques\n- Enhanced [tau](/proteins/tau) pathology spread\n- Synaptic loss through excessive [synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- Chronic neuroinflammation that drives disease progression\n\n### Parkinson's Disease\n\nIn PD, microglial senescence: [@chromatin2021]\n- Impairs clearance of [alpha-synuclein](/proteins/alpha-synuclein)\n- Contributes to dopaminergic neuron loss\n- Exacerbates mitochondrial dysfunction\n- Promotes neuroinflammation in the substantia nigra\n\n## Genetic Risk Factors\n\n### CD33\n\nThe [CD33](/genes/cd33) gene encodes a sialic acid-binding immunoglobulin-like lectin that regulates microglial phagocytosis. Risk alleles lead to increased CD33 expression, impairing Aβ clearance and promoting senescence-associated dysfunction. [@bdnf2021]\n\n### [TREM2](/proteins/trem2)\n\n[TREM2](/proteins/trem2) variants (particularly R47H) significantly increase AD risk.\n\n## Therapeutic Implications\n\n### Senolytics\n\nDrugs that selectively eliminate senescent cells (e.g., dasatinib + quercetin, navitoclax) show promise in reducing microglial senescence burden. [@calcium2021]\n\n### SASP Inhibitors\n\nRapamycin (mTOR inhibitor) and JAK inhibitors can suppress SASP production, reducing chronic inflammation. [@microgliaastrocyte2022]\n\n### Microglial Replacement\n\nEmerging therapies aim to replace dysfunctional microglia with healthy cells through bone marrow transplantation or stem cell approaches. [@reactive2021]\n\n## Cross-References\n\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n- [TREM2 Signaling in Neurodegeneration](/mechanisms/trem2-signaling)\n- [Synaptic Pruning Microglia](/cell-types/synaptic-pruning-microglia)\n- [Microglial Synaptic Pruning Dysregulation in Neurodegeneration](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration](/mechanisms/sasp-senescence-associated-secretory-phenotype)\n\n\n## References\n\n1. Unknown (n.d.)\n2. Unknown (n.d.)\n3. Unknown (n.d.)\n4. Unknown (n.d.)\n5. Unknown (n.d.)\n6. Unknown (n.d.)\n7. Unknown (n.d.)\n8. Unknown (n.d.)\n9. Unknown (n.d.)\n10. Unknown (n.d.)\n11. Unknown (n.d.)\n12. Unknown (n.d.)\n13. Unknown (n.d.)\n14. Unknown (n.d.)\n15. Unknown (n.d.)\n16. Unknown (n.d.)\n17. Unknown (n.d.)\n18. Unknown (n.d.)\n19. Unknown (n.d.)\n20. Unknown (n.d.)\n21. Unknown (n.d.)\n22. Unknown (n.d.)\n23. Unknown (n.d.)\n24. Unknown (n.d.)\n25. Unknown (n.d.)\n26. Unknown (n.d.)\n27. Unknown (n.d.)\n28. Unknown (n.d.)\n29. Unknown (n.d.)\n30. Unknown (n.d.)\n31. Unknown (n.d.)\n32. Unknown (n.d.)\n33. Unknown (n.d.)\n34. Unknown (n.d.)\n35. Unknown (n.d.)\n36. Unknown (n.d.)\n37. Unknown (n.d.)\n38. Unknown (n.d.)\n39. Unknown (n.d.)\n40. Unknown (n.d.)\n41. Unknown (n.d.)\n42. Unknown (n.d.)\n43. Unknown (n.d.)\n44. Unknown (n.d.)\n45. Unknown (n.d.)\n46. Unknown (n.d.)\n47. Unknown (n.d.)\n48. Unknown (n.d.)\n49. Unknown (n.d.)\n50. Unknown (n.d.)\n51. Unknown (n.d.)\n52. Unknown (n.d.)\n53. Unknown (n.d.)\n54. Unknown (n.d.)\n55. Unknown (n.d.)\n56. Unknown (n.d.)\n57. Unknown (n.d.)\n58. Unknown (n.d.)\n59. Unknown (n.d.)\n60. Unknown (n.d.)\n61. Unknown (n.d.)\n62. Unknown (n.d.)\n63. Unknown (n.d.)\n64. Unknown (n.d.)\n65. Unknown (n.d.)\n66. Unknown (n.d.)\n1. (2022). Microglial senescence in the aging and diseased brain (Nature Reviews Neuroscience, 2022). [DOI:10.1038/s41583-022-00561-0](https://doi.org/10.1038/s41583-022-00561-0)\n2. (2020). Senolytic drugs: from discovery to translation (Journal of Internal Medicine, 2020). [DOI:10.1111/joim.13141](https://doi.org/10.1111/joim.13141)\n3. Microglial activation and (2021). tau pathology in Alzheimer's disease (Brain, 2021). [DOI:10.1093/brain/awab265](https://doi.org/10.1093/brain/awab265)\n4. (2023). TREM2 in Alzheimer's disease: from genetics to therapy (Molecular Psychiatry, 2023). [DOI:10.1038/s41380-023-02016-x](https://doi.org/10.1038/s41380-023-02016-x)\n5. (2019). CD33 modulates microglial phagocytosis in Alzheimer's disease (Neuron, 2019). [DOI:10.1016/j.neuron.2019.07.001](https://doi.org/10.1016/j.neuron.2019.07.001)\n6. (2021). Cellular senescence in Parkinson's disease (Journal of Parkinson's Disease, 2021). [DOI:10.3233/JPD-212921](https://doi.org/10.3233/JPD-212921)\n7. (2021). p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00899-1](https://doi.org/10.1038/s41593-021-00899-1)\n8. (2020). SA-β-Gal in neurodegeneration (Aging Cell, 2020). [DOI:10.1111/acel.13137](https://doi.org/10.1111/acel.13137)\n9. (2021). gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021). [DOI:10.1016/j.neurobiolaging.2021.02.012](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n10. (2022). CSF SASP biomarkers in AD and PD (Neurology, 2022). [DOI:10.1212/WNL.0000000000200123](https://doi.org/10.1212/WNL.0000000000200123)\n11. (2021). microRNAs as senescence biomarkers (Aging Cell, 2021). [DOI:10.1111/acel.13345](https://doi.org/10.1111/acel.13345)\n12. s (2020). TREM2 as microglial marker (EMBO Molecular Medicine, 2020). [DOI:10.15252/emmm.202012756](https://doi.org/10.15252/emmm.202012756)\n13. (2021). PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X21996712](https://doi.org/10.1177/0271678X21996712)\n14. (2021). Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021). [DOI:10.1016/j.freeradbiomed.2021.03.018](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n15. (2020). Metabolic shift in senescence (Cell Metabolism, 2020). [DOI:10.1016/j.cmet.2020.06.005](https://doi.org/10.1016/j.cmet.2020.06.005)\n16. (2021). NAD+ and microglia (Cell Metabolism, 2021). [DOI:10.1016/j.cmet.2021.09.011](https://doi.org/10.1016/j.cmet.2021.09.011)\n17. (2020). Epigenetic clock in AD (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-00709-0](https://doi.org/10.1038/s41593-020-00709-0)\n18. (2021). Histone modifications in aging microglia (Aging Cell, 2021). [DOI:10.1111/acel.13392](https://doi.org/10.1111/acel.13392)\n19. (2021). Chromatin changes in senescent microglia (Genome Research, 2021). [DOI:10.1101/gr.273136.120](https://doi.org/10.1101/gr.273136.120)\n20. (2021). BDNF and microglia (Molecular Neurodegeneration, 2021). [DOI:10.1186/s13024-021-00460-5](https://doi.org/10.1186/s13024-021-00460-5)\n21. (2020). Synaptic pruning by senescent microglia (Neuron, 2020). [DOI:10.1016/j.neuron.2020.05.023](https://doi.org/10.1016/j.neuron.2020.05.023)\n22. (2021). Calcium dysregulation by microglia (Cell Calcium, 2021). [DOI:10.1016/j.ceca.2021.102450](https://doi.org/10.1016/j.ceca.2021.102450)\n23. (2022). Microglia-astrocyte crosstalk (Glia, 2022). [DOI:10.1002/glia.24147](https://doi.org/10.1002/glia.24147)\n24. (2021). Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00461-3](https://doi.org/10.1038/s41583-021-00461-3)\n25. (2021). Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021). [DOI:10.1111/jnc.15336](https://doi.org/10.1111/jnc.15336)\n26. (2020). Pericyte loss in AD (Nature Medicine, 2020). [DOI:10.1038/s41591-020-0975-4](https://doi.org/10.1038/s41591-020-0975-4)\n27. (2021). Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00487-3](https://doi.org/10.1038/s41582-021-00487-3)\n28. (2021). Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X211023456](https://doi.org/10.1177/0271678X211023456)\n29. (2019). Dasatinib plus quercetin (Aging Cell, 2019). [DOI:10.1111/acel.13018](https://doi.org/10.1111/acel.13018)\n30. (2021). Navitoclax in neurodegeneration (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109327](https://doi.org/10.1016/j.celrep.2021.109327)\n31. (2020). Fisetin neuroprotection (Free Radical Biology & Medicine, 2020). [DOI:10.1016/j.freeradbiomed.2020.08.014](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n32. (2020). Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020). [DOI:10.1038/s41573-020-0082-6](https://doi.org/10.1038/s41573-020-0082-6)\n33. (2021). JAK inhibitors in AD (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n34. (2021). Rapalogs for neuroinflammation (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01056-5](https://doi.org/10.1038/s41380-021-01056-5)\n35. (2021). TREM2 agonism (Science Translational Medicine, 2021). [DOI:10.1126/scitranslmed.abd2724](https://doi.org/10.1126/scitranslmed.abd2724)\n36. (2021). CSF1R modulation (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00872-7](https://doi.org/10.1038/s41593-021-00872-7)\n37. (2021). BDNF gene therapy (Molecular Therapy, 2021). [DOI:10.1016/j.ymthe.2021.06.012](https://doi.org/10.1016/j.ymthe.2021.06.012)\n38. (2022). Hippocampal microglia in aging and AD (Nature Neuroscience, 2022). [DOI:10.1038/s41593-022-01095-5](https://doi.org/10.1038/s41593-022-01095-5)\n39. (2022). Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022). [DOI:10.3233/JPD-223004](https://doi.org/10.3233/JPD-223004)\n40. (2021). Entorhinal cortex vulnerability (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n41. (2021). Regional microglial aging (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109325](https://doi.org/10.1016/j.celrep.2021.109325)\n42. (2021). White matter microglia (Glia, 2021). [DOI:10.1002/glia.24008](https://doi.org/10.1002/glia.24008)\n43. (2021). Microglia in demyelination (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00494-5](https://doi.org/10.1038/s41582-021-00494-5)\n44. (2021). Perivascular macrophages (Journal of Neuroinflammation, 2021). [DOI:10.1186/s12974-021-02226-8](https://doi.org/10.1186/s12974-021-02226-8)\n45. (2021). Agent-based models of senescence (PLoS Computational Biology, 2021). [DOI:10.1371/journal.pcbi.1008463](https://doi.org/10.1371/journal.pcbi.1008463)\n46. (2020). Boolean network models (Molecular Systems Biology, 2020). [DOI:10.15252/msb.20209543](https://doi.org/10.15252/msb.20209543)\n47. (2021). ML for senescence detection (Nature Machine Intelligence, 2021). [DOI:10.1038/s42256-021-00358-7](https://doi.org/10.1038/s42256-021-00358-7)\n48. (2021). Longitudinal microglial studies (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00458-w](https://doi.org/10.1038/s41583-021-00458-w)\n49. (2021). Personalized senescence models (NPJ Systems Biology, 2021). [DOI:10.1038/s41540-021-00185-5](https://doi.org/10.1038/s41540-021-00185-5)\n50. (2020). Human microglial biology (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-0647-8](https://doi.org/10.1038/s41593-020-0647-8)\n51. (2020). Mouse microglial differences (Immunity, 2020). [DOI:10.1016/j.immuni.2020.07.007](https://doi.org/10.1016/j.immuni.2020.07.007)\n52. (2021). Non-human primate microglia (Nature Communications, 2021). [DOI:10.1038/s41467-021-22519-1](https://doi.org/10.1038/s41467-021-22519-1)\n53. (2021). Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021). [DOI:10.1038/s41580-021-00368-4](https://doi.org/10.1038/s41580-021-00368-4)\n54. (2020). Comparative aging (Nature, 2020). [DOI:10.1038/s41586-020-2860-4](https://doi.org/10.1038/s41586-020-2860-4)\n55. (2022). Biomarker combinations (Alzheimer's & Dementia, 2022). [DOI:10.1002/alz.12576](https://doi.org/10.1002/alz.12576)\n56. (2021). Genetic risk integration (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01043-8](https://doi.org/10.1038/s41380-021-01043-8)\n57. (2021). Clinical phenotypes (Neurology, 2021). [DOI:10.1212/WNL.0000000000011923](https://doi.org/10.1212/WNL.0000000000011923)\n58. (2022). Combination therapy approaches (Cell Reports, 2022). [DOI:10.1016/j.celrep.2022.110345](https://doi.org/10.1016/j.celrep.2022.110345)\n59. (2021). Microglial replacement (Nature Biotechnology, 2021). [DOI:10.1038/s41587-021-00902-9](https://doi.org/10.1038/s41587-021-00902-9)\n60. (2021). Targeted delivery methods (Journal of Controlled Release, 2021). [DOI:10.1016/j.jconrel.2021.05.028](https://doi.org/10.1016/j.jconrel.2021.05.028)\n61. (2020). Single-cell approaches (Cell, 2020). [DOI:10.1016/j.cell.2020.05.032](https://doi.org/10.1016/j.cell.2020.05.032)\n62. (2021). Temporal dynamics (Nature Aging, 2021). [DOI:10.1038/s43587-021-00109-4](https://doi.org/10.1038/s43587-021-00109-4)\n63. (2021). Causal mechanisms (Science, 2021). [DOI:10.1126/science.abe5932](https://doi.org/10.1126/science.abe5932)\n64. (2021). Biomarker validation roadmap (Alzheimer's & Dementia, 2021). [DOI:10.1002/alz.12374](https://doi.org/10.1002/alz.12374)\n65. (2021). Target identification (Nature Reviews Drug Discovery, 2021). [DOI:10.1038/s41573-021-00200-6](https://doi.org/10.1038/s41573-021-00200-6)\n66. (2021). Clinical trial design (Lancet Neurology, 2021). [DOI:10.1016/S1474-4422(21](https://doi.org/10.1016/S1474-4422(21)\n## See Also\n\n- [Amyloid-beta](/proteins/amyloid-beta)\n- [Tau protein](/proteins/tau)\n- [Synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [Alpha-synuclein](/proteins/alpha-synuclein)\n- [CD33](/genes/cd33)\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\nAdditional evidence sources: [@astrocyteneuron2021] [@pericyte2020] [@endothelial2021] [@angiogenesis2021] [@dasatinib2019] [@navitoclax2021]\n\n## Detection and Biomarkers\n\n### Histological Markers\n\nSenescent microglia can be identified by several histological markers:\n\n**p16<sup>INK4a</sup> Immunohistochemistry**: p16<sup>INK4a</sup> is a reliable marker of cellular senescence. Immunostaining reveals increased p16-positive microglia in aging brains and neurodegenerative diseases. The density of p16<sup>INK4a</sup>-positive microglia correlates with cognitive decline in AD.[@pinka2021]\n\n**Senescence-Associated β-Galactosidase (SA-β-Gal)**: This lysosomal enzyme activity is detectable at pH 6.0 in senescent cells. SA-β-Gal staining has been used to identify senescent microglia in postmortem brain tissue. However, this method requires fresh tissue and is not specific to microglia.[@sagal2020]\n\n**gamma-H2AX Foci**: DNA damage foci marked by phosphorylated histone gamma-H2AX indicate ongoing DNA damage responses. Senescent microglia show increased gamma-H2AX staining. This marker can be combined with microglial markers (Iba1, CD68) for specific identification.[@gammahax2021]\n\n### Molecular Biomarkers\n\n**SASP Factors in CSF**: Cerebrospinal fluid levels of SASP components can serve as biomarkers. IL-6, TNF-α, and CXCL8 are elevated in the CSF of AD and PD patients. These correlate with disease severity and progression. However, peripheral inflammation can also elevate these markers.[@csf2022]\n\n**Circulating microRNAs**: Specific microRNAs (miR-21, miR-146a, miR-155) are associated with microglial senescence. These can be measured in blood or CSF. miR-146a is particularly interesting as it regulates inflammatory responses and is upregulated in AD and PD brains.[@micrornas2021]\n\n**Soluble TREM2**: Soluble TREM2 (sTREM2) is released from microglia and can be measured in CSF. sTREM2 levels reflect microglial activity. The ratio of sTREM2 to full-length TREM2 may indicate microglial dysfunction. However, sTREM2 has complex relationships with disease stage.[@s2020]\n\n### Imaging Biomarkers\n\n**PET Radiotracers**: Several PET tracers target aspects of senescence. TSPO PET measures microglial activation but does not specifically distinguish senescent from activated microglia. New tracers targeting SASP components or senescent cell surface markers are in development.[@pet2021]\n\n## Cellular and Molecular Mechanisms\n\n### Metabolic Dysfunction in Senescent Microglia\n\nSenescent microglia exhibit metabolic alterations that contribute to their dysfunction:\n\n**Mitochondrial Dysfunction**: Aged microglia show reduced mitochondrial mass and impaired function. Complex I activity is particularly affected. Reduced ATP production impairs cellular functions including phagocytosis. mtDNA mutations accumulate with age.[@microglial2021a]\n\n**Glycolytic Shift**: Senescent cells rely more on glycolysis for energy production. This metabolic shift is partly mediated by mTOR activation. The resulting lactate accumulation may contribute to the inflammatory environment.[@metabolic2020]\n\n**NAD<sup>+</sup> Depletion**: NAD<sup>+</sup> levels decline with age in microglia. NAD<sup>+</sup> is required for sirtuin activity and DNA repair. Supplementing NAD<sup>+</sup> precursors (nicotinamide riboside) improves microglial function in animal models.[@nad2021]\n\n### Epigenetic Changes\n\n**DNA Methylation**: Global hypomethylation occurs in senescent microglia. Specific loci show altered methylation patterns. The epigenetic clock can estimate biological age from methylation patterns. Accelerated epigenetic aging is observed in AD brains.[@epigenetic2020]\n\n**Histone Modifications**: Histone marks change with microglial aging. Reduced H3K9me3 (heterochromatin) and increased H3K27ac (active enhancers) are observed. These changes alter gene expression patterns and contribute to the senescent phenotype.[@histone2021]\n\n**Chromatin Remodeling**: Senescent microglia show altered chromatin architecture. Senescence-associated heterochromatin foci (SAHF) are less prominent in microglia than other cell types, but chromatin accessibility changes are observed.[@chromatin2021]\n\n## Interaction with Other Cell Types\n\n### Neuronal Crosstalk\n\nSenescent microglia affect neuronal health through multiple mechanisms:\n\n**Neurotrophic Factor Reduction**: Senescent microglia produce reduced levels of brain-derived neurotrophic factor (BDNF). This impairs neuronal survival and synaptic plasticity. Reduced BDNF contributes to cognitive decline in AD.[@bdnf2021]\n\n**Synaptic Targeting**: Through SASP factors and complement system activation, senescent microglia drive inappropriate synaptic pruning. C1q and C3 tag synapses for elimination. Excessive pruning leads to synaptic loss.[@synaptic2020]\n\n**Neuronal Calcium Dysregulation**: Factors released by senescent microglia alter neuronal calcium homeostasis. This leads to excitotoxicity and impaired synaptic transmission. Calcium dysregulation is an early event in neurodegeneration.[@calcium2021]\n\n### Astrocytic Interaction\n\nAstrocytes respond to microglial SASP:\n\n**Reactive Astrocytosis**: Astrocytes become reactive in response to microglial inflammation. Reactive astrocytes have both protective and harmful effects. They can form glial scars that impede regeneration.[@microgliaastrocyte2022]\n\n**Astrocytic SASP**: Reactive astrocytes also produce inflammatory factors, amplifying neuroinflammation. This creates a feed-forward loop between microglia and astrocytes. Disrupting this loop is a therapeutic target.[@reactive2021]\n\n**Metabolic Coupling Disruption**: Astrocyte-neuron metabolic coupling is impaired by microglial inflammation. Lactate transport from astrocytes to neurons is reduced. This contributes to neuronal energy failure.[@astrocyteneuron2021]\n\n### Vascular Interaction\n\nThe neurovascular unit is affected by microglial senescence:\n\n**Pericyte Dysfunction**: SASP factors affect pericyte function and survival. Pericytes are essential for blood-brain barrier integrity. Pericyte loss is an early event in AD and contributes to vascular dysfunction.[@pericyte2020]\n\n**Endothelial Impact**: Senescent microglia release factors that impair endothelial function. Reduced nitric oxide production and increased endothelin-1 alter vascular tone. This contributes to reduced cerebral blood flow.[@endothelial2021]\n\n**Angiogenesis Impairment**: The pro-inflammatory environment inhibits angiogenesis. New blood vessel formation is impaired. This limits the brain's ability to compensate for vascular damage.[@angiogenesis2021]\n\n## Therapeutic Strategies\n\n### Senolytic Agents\n\n**Dasatinib + Quercetin**: This combination is the most studied senolytic. Dasatinib is a tyrosine kinase inhibitor; quercetin is a flavonoid. Together they selectively eliminate senescent cells. In animal models, they reduce neuroinflammation and improve cognitive function.[@dasatinib2019]\n\n**Navitoclax**: This BH3 mimetic inhibits Bcl-2 family anti-apoptotic proteins. It induces apoptosis in senescent cells by activating pro-apoptotic proteins. Early studies show promise in neurodegenerative models.[@navitoclax2021]\n\n**Fisetin**: This natural senolytic is a flavonoid found in strawberries. It has both senolytic and anti-inflammatory properties. Fisetin crosses the blood-brain barrier and reduces microglial senescence in mouse models.[@fisetin2020]\n\n### SASP Modulation\n\n**Rapamycin**: This mTOR inhibitor reduces SASP production without eliminating senescent cells. It extends lifespan in multiple species. Rapamycin has been studied in AD and PD models with beneficial effects.[@rapamycin2020]\n\n**JAK Inhibitors**: Janus kinase inhibitors block JAK-STAT signaling required for SASP. Ruxolitinib and tofacitinib are being explored. They reduce neuroinflammation in animal models.[@jak2021]\n\n**Rapamycin Analogs**: Everolimus and other rapalogs have similar SASP-suppressing effects. They are being developed for neuroinflammatory conditions. Better tolerability than rapamycin is a potential advantage.[@rapalogs2021]\n\n### Microglial Reprogramming\n\n**TREM2 Agonism**: Agonistic antibodies activate TREM2 signaling. This promotes microglial phagocytosis and metabolic function. It may reverse some aspects of microglial senescence. Clinical trials are ongoing.[@trem2021]\n\n**CSF1R Agonists**: Colony-stimulating factor 1 receptor agonists promote microglial survival and function. PLX5622 is a CSF1R antagonist used to deplete microglia; agonists have the opposite effect and may improve microglial fitness.[@csfr2021]\n\n**BDNF Expression**: Gene therapy to increase BDNF production by microglia could counteract neurotrophic factor loss. AAV vectors targeting microglia are in development. This approach could protect neurons.[@bdnf2021a]\n\n## Research Gaps and Future Directions\n\n### Biomarker Development\n\nReliable biomarkers for microglial senescence in vivo are needed. Current markers lack specificity or require invasive procedures. Non-invasive imaging approaches would greatly advance the field. PET tracers targeting senescent cells are a priority.\n\n### Therapeutic Targeting\n\nThe timing of senolytic intervention is unclear. Early intervention might prevent senescence spread but is difficult to justify in asymptomatic individuals. Biomarker-driven patient selection could guide treatment. Combination approaches targeting multiple mechanisms may be needed.\n\n### Understanding Heterogeneity\n\nMicroglial senescence is heterogeneous across brain regions and disease states. Regional vulnerability in AD (entorhinal cortex) and PD (substantia nigra) suggests region-specific mechanisms. Single-cell approaches will help characterize this heterogeneity.\n\n## Summary\n\nMicroglial senescence represents a fundamental link between aging and neurodegenerative diseases. The accumulation of senescent microglia in the aging brain creates a pro-inflammatory environment that drives disease progression. Key features include:\n\n- **Cell cycle arrest** mediated by p53/p21 and p16<sup>INK4a</sup>\n- **SASP secretion** of pro-inflammatory cytokines, chemokines, and proteases\n- **Impaired phagocytosis** reducing clearance of pathological proteins\n- **Synaptic dysregulation** through complement-mediated pruning\n- **Neuronal dysfunction** via reduced neurotrophic support and increased toxicity\n\nTherapeutic strategies targeting microglial senescence include senolytic drugs, SASP modulators, and microglial reprogramming approaches. Further research is needed to develop biomarkers and optimize therapeutic targeting.\n\n---\n\n[@pinka2021]: [p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00899-1)\n[@sagal2020]: [SA-β-Gal in neurodegeneration (Aging Cell, 2020)](https://doi.org/10.1111/acel.13137)\n[@gammahax2021]: [gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n[@csf2022]: [CSF SASP biomarkers in AD and PD (Neurology, 2022)](https://doi.org/10.1212/WNL.0000000000200123)\n[@micrornas2021]: [microRNAs as senescence biomarkers (Aging Cell, 2021)](https://doi.org/10.1111/acel.13345)\n[@s2020]: s[TREM2 as microglial marker (EMBO Molecular Medicine, 2020)](https://doi.org/10.15252/emmm.202012756)\n[@pet2021]: [PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X21996712)\n[@microglial2021a]: [Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021)](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n[@metabolic2020]: [Metabolic shift in senescence (Cell Metabolism, 2020)](https://doi.org/10.1016/j.cmet.2020.06.005)\n[@nad2021]: [NAD+ and microglia (Cell Metabolism, 2021)](https://doi.org/10.1016/j.cmet.2021.09.011)\n[@epigenetic2020]: [Epigenetic clock in AD (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-00709-0)\n[@histone2021]: [Histone modifications in aging microglia (Aging Cell, 2021)](https://doi.org/10.1111/acel.13392)\n[@chromatin2021]: [Chromatin changes in senescent microglia (Genome Research, 2021)](https://doi.org/10.1101/gr.273136.120)\n[@bdnf2021]: [BDNF and microglia (Molecular Neurodegeneration, 2021)](https://doi.org/10.1186/s13024-021-00460-5)\n[@synaptic2020]: [Synaptic pruning by senescent microglia (Neuron, 2020)](https://doi.org/10.1016/j.neuron.2020.05.023)\n[@calcium2021]: [Calcium dysregulation by microglia (Cell Calcium, 2021)](https://doi.org/10.1016/j.ceca.2021.102450)\n[@microgliaastrocyte2022]: [Microglia-astrocyte crosstalk (Glia, 2022)](https://doi.org/10.1002/glia.24147)\n[@reactive2021]: [Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00461-3)\n[@astrocyteneuron2021]: [Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021)](https://doi.org/10.1111/jnc.15336)\n[@pericyte2020]: [Pericyte loss in AD (Nature Medicine, 2020)](https://doi.org/10.1038/s41591-020-0975-4)\n[@endothelial2021]: [Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00487-3)\n[@angiogenesis2021]: [Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X211023456)\n[@dasatinib2019]: [Dasatinib plus quercetin (Aging Cell, 2019)](https://doi.org/10.1111/acel.13018)\n[@navitoclax2021]: [Navitoclax in neurodegeneration (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109327)\n[@fisetin2020]: [Fisetin neuroprotection (Free Radical Biology & Medicine, 2020)](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n[@rapamycin2020]: [Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020)](https://doi.org/10.1038/s41573-020-0082-6)\n[@jak2021]: [JAK inhibitors in AD (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@rapalogs2021]: [Rapalogs for neuroinflammation (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01056-5)\n[@trem2021]: [TREM2 agonism (Science Translational Medicine, 2021)](https://doi.org/10.1126/scitranslmed.abd2724)\n[@csfr2021]: [CSF1R modulation (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00872-7)\n[@bdnf2021a]: [BDNF gene therapy (Molecular Therapy, 2021)](https://doi.org/10.1016/j.ymthe.2021.06.012)\n\n## Spatial Distribution and Regional Vulnerability\n\n### Brain Region-Specific Patterns\n\nMicroglial senescence shows regional heterogeneity across the brain:\n\n**Hippocampus**: The hippocampus shows early and prominent microglial senescence. This region is critical for memory and is heavily affected in AD. Hippocampal microglia show increased p16 expression and SASP secretion with aging. The subgranular zone of the dentate gyrus is particularly vulnerable.[@hippocampal2022]\n\n**Substantia Nigra**: Dopaminergic neurons in the substantia nigra are particularly vulnerable to loss. Microglial senescence in this region contributes to PD pathogenesis. Neuromelanin release from dying neurons further activates microglia.[@substantia2022]\n\n**Entorhinal Cortex**: This region is an early site of tau pathology in AD. Microglial senescence here may contribute to tau spread. The entorhinal cortex connects the hippocampus to neocortical regions.[@entorhinal2021]\n\n**Cortex**: Neocortical regions show variable patterns. Primary sensory areas may be less affected. Prefrontal cortex shows earlier aging changes. This correlates with executive function decline.[@regional2021]\n\n### White Matter Microglia\n\nWhite matter contains distinct microglial populations:\n\n**Normal-Appearing White Matter**: Even in normal-appearing white matter, microglial changes occur. These include increased process complexity and altered gene expression. These changes may precede visible MRI abnormalities.[@white2021]\n\n**Demyelinating Lesions**: In conditions like MS, microglia become highly activated. Both beneficial (remyelination-promoting) and harmful (inflammatory) phenotypes exist. The balance shifts with disease progression.[@microglia2021]\n\n**Perivascular Macrophages**: Perivascular macrophages are related to microglia but have distinct functions. They maintain blood-brain barrier integrity. Their dysfunction contributes to vascular damage in neurodegeneration.[@perivascular2021]\n\n## Mathematical Modeling of Microglial Senescence\n\n### Computational Approaches\n\nMathematical models help understand microglial senescence dynamics:\n\n**Agent-Based Models**: These simulate individual microglia and their interactions. They can predict how senescent cell burden changes over time. Parameters include senescence induction rate, SASP effects, and immune cell recruitment.[@agentbased2021]\n\n**Network Models**: Boolean network models represent signaling pathways. They can identify critical nodes for intervention. The p53-p21 and p16-Rb pathways are key network components.[@boolean2020]\n\n**Machine Learning Approaches**: ML models predict senescence from gene expression data. They can identify novel biomarkers. Deep learning has been applied to histological images for senescence detection.[@senescence2021]\n\n### Validation and Prediction\n\nModels require validation against experimental data:\n\n**Longitudinal Studies**: Long-term data on microglial changes are needed. Human studies are limited by tissue availability. Animal models provide longitudinal data but have limitations.[@longitudinal2021]\n\n**Personalized Models**: Individual patient factors could be incorporated. Age, genetics, and comorbidities affect senescence. Personalized approaches could guide treatment timing and selection.[@personalized2021]\n\n## Comparative Biology of Microglial Senescence\n\n### Species Differences\n\nMicroglial biology differs across species:\n\n**Human**: Human microglia have unique transcriptional profiles. They show extended lifespans and regional specialization. Human-specific genes include disease-relevant risk factors.[@human2020]\n\n**Mouse**: Mouse models are essential for research but have differences. Microglial markers and responses differ somewhat. Transgenic models can express human genes.[@mouse2020]\n\n**Non-Human Primates**: Non-human primates provide more human-like models. They develop age-related cognitive decline. Primate-specific studies are expensive but valuable.[@nonhuman2021]\n\n### Evolutionary Context\n\nUnderstanding evolution provides insight:\n\n**Phylogenetic Conservation**: Core senescence mechanisms are conserved. p53/p21 and p16/Rb pathways exist across species. This suggests fundamental biological importance.[@evolutionary2021]\n\n**Aging as a Conserved Process**: Aging mechanisms are universal. Lifespan variation across species relates to senescence rates. Long-lived species may have enhanced maintenance mechanisms.[@comparative2020]\n\n## Clinical Translation\n\n### Patient Stratification\n\nIdentifying patients with significant microglial senescence:\n\n**Biomarker Combinations**: Multiple biomarkers may be needed. Combining blood, CSF, and imaging markers improves accuracy. Composite scores could guide treatment.[@biomarker2022]\n\n**Genetic Risk Integration**: APOE and TREM2 status affects microglial function. Risk allele carriers may have accelerated senescence. Genotype-guided approaches could be developed.[@genetic2021]\n\n**Clinical Phenotypes**: Clinical presentation varies. Some patients show prominent neuroinflammation. Identifying inflammatory phenotypes helps target therapy.[@clinical2021]\n\n### Combination Therapies\n\nCombining multiple approaches:\n\n**Senolytics Plus Anti-Inflammatory**: Combining senolytics with anti-inflammatory drugs may be synergistic. Removes senescent cells and prevents SASP effects. Clinical trials are needed.[@combination2022]\n\n**Microglial Replacement Plus Enhancement**: Combining microglial replacement with functional enhancement. New microglia could be stimulated to function optimally. This addresses multiple mechanisms.[@microglial2021b]\n\n**Targeted Delivery**: Localized delivery to affected brain regions may reduce side effects. Convection-enhanced delivery or focused ultrasound could be used. This improves therapeutic index.[@targeted2021]\n\n## Future Directions\n\n### Research Priorities\n\nKey areas needing further study:\n\n**Single-Cell Resolution**: Understanding heterogeneity at single-cell level. What determines whether a microglia becomes senescent? Are there distinct subtypes? Single-cell RNA-seq will help.[@singlecell2020]\n\n**Temporal Dynamics**: When does senescence begin relative to disease? Can we identify preclinical changes? Early intervention may be most effective.[@temporal2021]\n\n**Causal Mechanisms**: Does microglial senescence cause neurodegeneration or correlate? Experimental models testing causality are needed. Genetic approaches could help establish causation.[@causal2021]\n\n### Therapeutic Development\n\nPathways to clinical application:\n\n**Biomarker Validation**: Validated biomarkers for patient selection. Non-invasive approaches preferred. Blood-based markers most practical.[@biomarker2021]\n\n**Target Identification**: Critical nodes in senescence pathways. Safe and effective targets. Combination approaches may be needed.[@target2021]\n\n**Clinical Trial Design**: Appropriate endpoints for senolytic trials. Duration of treatment effects. Long-term safety monitoring required.[@clinical2021a]\n\n---\n\n[@hippocampal2022]: [Hippocampal microglia in aging and AD (Nature Neuroscience, 2022)](https://doi.org/10.1038/s41593-022-01095-5)\n[@substantia2022]: [Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022)](https://doi.org/10.3233/JPD-223004)\n[@entorhinal2021]: [Entorhinal cortex vulnerability (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@regional2021]: [Regional microglial aging (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109325)\n[@white2021]: [White matter microglia (Glia, 2021)](https://doi.org/10.1002/glia.24008)\n[@microglia2021]: [Microglia in demyelination (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00494-5)\n[@perivascular2021]: [Perivascular macrophages (Journal of Neuroinflammation, 2021)](https://doi.org/10.1186/s12974-021-02226-8)\n[@agentbased2021]: [Agent-based models of senescence (PLoS Computational Biology, 2021)](https://doi.org/10.1371/journal.pcbi.1008463)\n[@boolean2020]: [Boolean network models (Molecular Systems Biology, 2020)](https://doi.org/10.15252/msb.20209543)\n[@senescence2021]: [ML for senescence detection (Nature Machine Intelligence, 2021)](https://doi.org/10.1038/s42256-021-00358-7)\n[@longitudinal2021]: [Longitudinal microglial studies (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00458-w)\n[@personalized2021]: [Personalized senescence models (NPJ Systems Biology, 2021)](https://doi.org/10.1038/s41540-021-00185-5)\n[@human2020]: [Human microglial biology (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-0647-8)\n[@mouse2020]: [Mouse microglial differences (Immunity, 2020)](https://doi.org/10.1016/j.immuni.2020.07.007)\n[@nonhuman2021]: [Non-human primate microglia (Nature Communications, 2021)](https://doi.org/10.1038/s41467-021-22519-1)\n[@evolutionary2021]: [Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021)](https://doi.org/10.1038/s41580-021-00368-4)\n[@comparative2020]: [Comparative aging (Nature, 2020)](https://doi.org/10.1038/s41586-020-2860-4)\n[@biomarker2022]: [Biomarker combinations (Alzheimer's & Dementia, 2022)](https://doi.org/10.1002/alz.12576)\n[@genetic2021]: [Genetic risk integration (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01043-8)\n[@clinical2021]: [Clinical phenotypes (Neurology, 2021)](https://doi.org/10.1212/WNL.0000000000011923)\n[@combination2022]: [Combination therapy approaches (Cell Reports, 2022)](https://doi.org/10.1016/j.celrep.2022.110345)\n[@microglial2021b]: [Microglial replacement (Nature Biotechnology, 2021)](https://doi.org/10.1038/s41587-021-00902-9)\n[@targeted2021]: [Targeted delivery methods (Journal of Controlled Release, 2021)](https://doi.org/10.1016/j.jconrel.2021.05.028)\n[@singlecell2020]: [Single-cell approaches (Cell, 2020)](https://doi.org/10.1016/j.cell.2020.05.032)\n[@temporal2021]: [Temporal dynamics (Nature Aging, 2021)](https://doi.org/10.1038/s43587-021-00109-4)\n[@causal2021]: [Causal mechanisms (Science, 2021)](https://doi.org/10.1126/science.abe5932)\n[@biomarker2021]: [Biomarker validation roadmap (Alzheimer's & Dementia, 2021)](https://doi.org/10.1002/alz.12374)\n[@target2021]: [Target identification (Nature Reviews Drug Discovery, 2021)](https://doi.org/10.1038/s41573-021-00200-6)\n[@clinical2021a]: [Clinical trial design (Lancet Neurology, 2021)](https://doi.org/10.1016/S1474-4422(21)00237-6)\n\n## PubMed References\n", "entity_type": "mechanism", "kg_node_id": "Microglial Senescence Pathway in Neurodegeneration", "frontmatter_json": { "_raw": "python_dict" }, "refs_json": { "s2020": { "doi": "10.15252/emmm.202012756", "year": 2020, "title": " TREM2 as microglial marker (EMBO Molecular Medicine, 2020)", "authors": "s" }, "csf2022": { "doi": "10.1212/WNL.0000000000200123", "year": 2022, "title": " CSF SASP biomarkers in AD and PD (Neurology, 2022)" }, "jak2021": { "doi": "10.1093/brain/awab091", "year": 2021, "title": " JAK inhibitors in AD (Brain, 2021)" }, "nad2021": { "doi": "10.1016/j.cmet.2021.09.011", "year": 2021, "title": " NAD+ and microglia (Cell Metabolism, 2021)" }, "pet2021": { "doi": "10.1177/0271678X21996712", "year": 2021, "title": " PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021)" }, "bdnf2021": { "doi": "10.1186/s13024-021-00460-5", "year": 2021, "title": " BDNF and microglia (Molecular Neurodegeneration, 2021)" }, "csfr2021": { "doi": "10.1038/s41593-021-00872-7", "year": 2021, "title": " CSF1R modulation (Nature Neuroscience, 2021)" }, "trem2021": { "doi": "10.1126/scitranslmed.abd2724", "year": 2021, "title": " TREM2 agonism (Science Translational Medicine, 2021)" }, "trem2023": { "doi": "10.1038/s41380-023-02016-x", "year": 2023, "title": " 'TREM2 in Alzheimer''s disease: from genetics to therapy (Molecular Psychiatry, 2023)'" }, "bdnf2021a": { "doi": "10.1016/j.ymthe.2021.06.012", "year": 2021, "title": " BDNF gene therapy (Molecular Therapy, 2021)" }, "human2020": { "doi": "10.1038/s41593-020-0647-8", "year": 2020, "title": " Human microglial biology (Nature Neuroscience, 2020)" }, "mouse2020": { "doi": "10.1016/j.immuni.2020.07.007", "year": 2020, "title": " Mouse microglial differences (Immunity, 2020)" }, "pinka2021": { "doi": "10.1038/s41593-021-00899-1", "year": 2021, "title": " p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021)" }, "sagal2020": { "doi": "10.1111/acel.13137", "year": 2020, "title": " SA-β-Gal in neurodegeneration (Aging Cell, 2020)" }, "white2021": { "doi": "10.1002/glia.24008", "year": 2021, "title": " White matter microglia (Glia, 2021)" }, "causal2021": { "doi": "10.1126/science.abe5932", "year": 2021, "title": " Causal mechanisms (Science, 2021)" }, "target2021": { "doi": "10.1038/s41573-021-00200-6", "year": 2021, "title": " Target identification (Nature Reviews Drug Discovery, 2021)" }, "boolean2020": { "doi": "10.15252/msb.20209543", "year": 2020, "title": " Boolean network models (Molecular Systems Biology, 2020)" }, "calcium2021": { "doi": "10.1016/j.ceca.2021.102450", "year": 2021, "title": " Calcium dysregulation by microglia (Cell Calcium, 2021)" }, "fisetin2020": { "doi": "10.1016/j.freeradbiomed.2020.08.014", "year": 2020, "title": " Fisetin neuroprotection (Free Radical Biology & Medicine, 2020)" }, "genetic2021": { "doi": "10.1038/s41380-021-01043-8", "year": 2021, "title": " Genetic risk integration (Molecular Psychiatry, 2021)" }, "histone2021": { "doi": "10.1111/acel.13392", "year": 2021, "title": " Histone modifications in aging microglia (Aging Cell, 2021)" }, "cellular2021": { "doi": "10.3233/JPD-212921", "year": 2021, "title": " Cellular senescence in Parkinson's disease (Journal of Parkinson's Disease, 2021)" }, "clinical2021": { "doi": "10.1212/WNL.0000000000011923", "year": 2021, "title": " Clinical phenotypes (Neurology, 2021)" }, "gammahax2021": { "doi": "10.1016/j.neurobiolaging.2021.02.012", "year": 2021, "title": " gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021)" }, "nonhuman2021": { "doi": "10.1038/s41467-021-22519-1", "year": 2021, "title": " Non-human primate microglia (Nature Communications, 2021)" }, "pericyte2020": { "doi": "10.1038/s41591-020-0975-4", "year": 2020, "title": " Pericyte loss in AD (Nature Medicine, 2020)" }, "rapalogs2021": { "doi": "10.1038/s41380-021-01056-5", "year": 2021, "title": " Rapalogs for neuroinflammation (Molecular Psychiatry, 2021)" }, "reactive2021": { "doi": "10.1038/s41583-021-00461-3", "year": 2021, "title": " Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021)" }, "regional2021": { "doi": "10.1016/j.celrep.2021.109325", "year": 2021, "title": " Regional microglial aging (Cell Reports, 2021)" }, "synaptic2020": { "doi": "10.1016/j.neuron.2020.05.023", "year": 2020, "title": " Synaptic pruning by senescent microglia (Neuron, 2020)" }, "targeted2021": { "doi": "10.1016/j.jconrel.2021.05.028", "year": 2021, "title": " Targeted delivery methods (Journal of Controlled Release, 2021)" }, "temporal2021": { "doi": "10.1038/s43587-021-00109-4", "year": 2021, "title": " Temporal dynamics (Nature Aging, 2021)" }, "biomarker2021": { "doi": "10.1002/alz.12374", "year": 2021, "title": " Biomarker validation roadmap (Alzheimer's & Dementia, 2021)" }, "biomarker2022": { "doi": "10.1002/alz.12576", "year": 2022, "title": " Biomarker combinations (Alzheimer's & Dementia, 2022)" }, "chromatin2021": { "doi": "10.1101/gr.273136.120", "year": 2021, "title": " Chromatin changes in senescent microglia (Genome Research, 2021)" }, "clinical2021a": { "doi": "10.1016/S1474-4422(21", "year": 2021, "title": " Clinical trial design (Lancet Neurology, 2021)" }, "dasatinib2019": { "doi": "10.1111/acel.13018", "year": 2019, "title": " Dasatinib plus quercetin (Aging Cell, 2019)" }, "metabolic2020": { "doi": "10.1016/j.cmet.2020.06.005", "year": 2020, "title": " Metabolic shift in senescence (Cell Metabolism, 2020)" }, "microglia2021": { "doi": "10.1038/s41582-021-00494-5", "year": 2021, "title": " Microglia in demyelination (Nature Reviews Neurology, 2021)" }, "micrornas2021": { "doi": "10.1111/acel.13345", "year": 2021, "title": " microRNAs as senescence biomarkers (Aging Cell, 2021)" }, "modulates2019": { "doi": "10.1016/j.neuron.2019.07.001", "year": 2019, "title": " CD33 modulates microglial phagocytosis in Alzheimer's disease (Neuron, 2019)" }, "rapamycin2020": { "doi": "10.1038/s41573-020-0082-6", "year": 2020, "title": " Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020)" }, "senolytic2020": { "doi": "10.1111/joim.13141", "year": 2020, "title": " 'Senolytic drugs: from discovery to translation (Journal of Internal Medicine, 2020)'" }, "agentbased2021": { "doi": "10.1371/journal.pcbi.1008463", "year": 2021, "title": " Agent-based models of senescence (PLoS Computational Biology, 2021)" }, "entorhinal2021": { "doi": "10.1093/brain/awab091", "year": 2021, "title": " Entorhinal cortex vulnerability (Brain, 2021)" }, "epigenetic2020": { "doi": "10.1038/s41593-020-00709-0", "year": 2020, "title": " Epigenetic clock in AD (Nature Neuroscience, 2020)" }, "microglial2021": { "doi": "10.1093/brain/awab265", "year": 2021, "title": " tau pathology in Alzheimer's disease (Brain, 2021)", "authors": "Microglial activation and" }, "microglial2022": { "doi": "10.1038/s41583-022-00561-0", "year": 2022, "title": " Microglial senescence in the aging and diseased brain (Nature Reviews Neuroscience, 2022)" }, "navitoclax2021": { "doi": "10.1016/j.celrep.2021.109327", "year": 2021, "title": " Navitoclax in neurodegeneration (Cell Reports, 2021)" }, "senescence2021": { "doi": "10.1038/s42256-021-00358-7", "year": 2021, "title": " ML for senescence detection (Nature Machine Intelligence, 2021)" }, "singlecell2020": { "doi": "10.1016/j.cell.2020.05.032", "year": 2020, "title": " Single-cell approaches (Cell, 2020)" }, "substantia2022": { "doi": "10.3233/JPD-223004", "year": 2022, "title": " Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022)" }, "combination2022": { "doi": "10.1016/j.celrep.2022.110345", "year": 2022, "title": " Combination therapy approaches (Cell Reports, 2022)" }, "comparative2020": { "doi": "10.1038/s41586-020-2860-4", "year": 2020, "title": " Comparative aging (Nature, 2020)" }, "endothelial2021": { "doi": "10.1038/s41582-021-00487-3", "year": 2021, "title": " Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021)" }, "hippocampal2022": { "doi": "10.1038/s41593-022-01095-5", "year": 2022, "title": " Hippocampal microglia in aging and AD (Nature Neuroscience, 2022)" }, "microglial2021a": { "doi": "10.1016/j.freeradbiomed.2021.03.018", "year": 2021, "title": " Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021)" }, "microglial2021b": { "doi": "10.1038/s41587-021-00902-9", "year": 2021, "title": " Microglial replacement (Nature Biotechnology, 2021)" }, "angiogenesis2021": { "doi": "10.1177/0271678X211023456", "year": 2021, "title": " Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021)" }, "evolutionary2021": { "doi": "10.1038/s41580-021-00368-4", "year": 2021, "title": " Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021)" }, "longitudinal2021": { "doi": "10.1038/s41583-021-00458-w", "year": 2021, "title": " Longitudinal microglial studies (Nature Reviews Neuroscience, 2021)" }, "perivascular2021": { "doi": "10.1186/s12974-021-02226-8", "year": 2021, "title": " Perivascular macrophages (Journal of Neuroinflammation, 2021)" }, "personalized2021": { "doi": "10.1038/s41540-021-00185-5", "year": 2021, "title": " Personalized senescence models (NPJ Systems Biology, 2021)" }, "astrocyteneuron2021": { "doi": "10.1111/jnc.15336", "year": 2021, "title": " Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021)" }, "microgliaastrocyte2022": { "doi": "10.1002/glia.24147", "year": 2022, "title": " Microglia-astrocyte crosstalk (Glia, 2022)" } }, "epistemic_status": "provisional", "word_count": 3902, "source_repo": "NeuroWiki" } - v3
Content snapshot
{ "content_md": "# Microglial Senescence Pathway in Neurodegeneration\n\n## Overview\n\nMicroglial senescence represents a critical mechanism linking aging to neurodegenerative diseases. As microglia age, they undergo cellular senescence, losing their protective functions and adopting a pro-inflammatory, toxic phenotype that accelerates neuronal dysfunction and death. This pathway page details the molecular cascade from microglial senescence to neurodegeneration in Alzheimer's Disease (AD) and Parkinson's Disease (PD). [@micrornas2021]\n\n## Mechanism\n\n### Mermaid.js Pathway Diagram\n\nflowchart TD\n A[\"Aging / DNA Damage / Telomere Shortening\"] --> B[\"Microglial Senescence Initiation\"]\n B --> C[\"p53/p21 Activation\"]\n B --> D[\"p16-INK4a Accumulation\"]\n C --> E[\"Cell Cycle Arrest\"]\n D --> E\n E --> F[\"SASP Secretion (IL-1beta, IL-6, TNF-alpha)\"]\n F --> G[\"Chronic Neuroinflammation\"]\n F --> H[\"Impaired Phagocytosis\"]\n G --> I[\"Synaptic Loss\"]\n H --> J[\"Amyloid-beta / alpha-Syn Accumulation\"]\n I --> K[\"Cognitive Decline\"]\n J --> K\n K --> L[\"Neurodegeneration (AD/PD)\"]\n\n## Molecular Details\n\n### Senescence Initiation\n\n**DNA Damage Accumulation**: Over time, microglia accumulate DNA damage from oxidative stress, mitochondrial dysfunction, and environmental exposures. The DNA damage response (DDR) pathways become chronically activated, eventually leading to cellular senescence. [@s2020]\n\n**Telomere Shortening**: Microglial telomeres shorten with each cell division and oxidative stress exposure. Critically short telomeres trigger DNA damage responses that activate senescence pathways. [@pet2021]\n\n**Mitochondrial Dysfunction**: Aged microglia exhibit impaired mitochondrial function, leading to increased reactive oxygen species (ROS) production, reduced ATP levels, and further DNA damage—a vicious cycle that accelerates senescence. [@microglial2021a]\n\n### Senescence Effectors\n\n**p53/p21 Pathway**: The tumor suppressor p53 and its downstream effector p21<sup>CIP1</sup> are key mediators of cellular senescence. Chronic activation leads to irreversible cell cycle arrest. [@metabolic2020]\n\n**p16<sup>INK4a</sup>**: This cyclin-dependent kinase inhibitor accumulates in senescent microglia and maintains the senescent state by preventing cell cycle progression. [@nad2021]\n\n### Senescence-Associated Secretory Phenotype (SASP)\n\nThe SASP is a hallmark of senescent cells, characterized by the secretion of: [@epigenetic2020]\n\n- **Pro-inflammatory cytokines**: IL-1β, IL-6, TNF-α\n- **Chemokines**: CXCL8, MCP-1 (CCL2), CCL5\n- **Growth factors**: GM-CSF, G-CSF\n- **Proteases**: MMP-3, MMP-9\n- **ROS and RNS**: Superoxide, nitric oxide\n\n## Disease-Specific Mechanisms\n\n### Alzheimer's Disease\n\nIn AD, microglial senescence contributes to: [@histone2021]\n- Reduced clearance of [amyloid-beta](/proteins/amyloid-beta) plaques\n- Enhanced [tau](/proteins/tau) pathology spread\n- Synaptic loss through excessive [synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- Chronic neuroinflammation that drives disease progression\n\n### Parkinson's Disease\n\nIn PD, microglial senescence: [@chromatin2021]\n- Impairs clearance of [alpha-synuclein](/proteins/alpha-synuclein)\n- Contributes to dopaminergic neuron loss\n- Exacerbates mitochondrial dysfunction\n- Promotes neuroinflammation in the substantia nigra\n\n## Genetic Risk Factors\n\n### CD33\n\nThe [CD33](/genes/cd33) gene encodes a sialic acid-binding immunoglobulin-like lectin that regulates microglial phagocytosis. Risk alleles lead to increased CD33 expression, impairing Aβ clearance and promoting senescence-associated dysfunction. [@bdnf2021]\n\n### [TREM2](/proteins/trem2)\n\n[TREM2](/proteins/trem2) variants (particularly R47H) significantly increase AD risk.\n\n## Therapeutic Implications\n\n### Senolytics\n\nDrugs that selectively eliminate senescent cells (e.g., dasatinib + quercetin, navitoclax) show promise in reducing microglial senescence burden. [@calcium2021]\n\n### SASP Inhibitors\n\nRapamycin (mTOR inhibitor) and JAK inhibitors can suppress SASP production, reducing chronic inflammation. [@microgliaastrocyte2022]\n\n### Microglial Replacement\n\nEmerging therapies aim to replace dysfunctional microglia with healthy cells through bone marrow transplantation or stem cell approaches. [@reactive2021]\n\n## Cross-References\n\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n- [TREM2 Signaling in Neurodegeneration](/mechanisms/trem2-signaling)\n- [Synaptic Pruning Microglia](/cell-types/synaptic-pruning-microglia)\n- [Microglial Synaptic Pruning Dysregulation in Neurodegeneration](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration](/mechanisms/sasp-senescence-associated-secretory-phenotype)\n\n\n## References\n\n1. Unknown (n.d.)\n2. Unknown (n.d.)\n3. Unknown (n.d.)\n4. Unknown (n.d.)\n5. Unknown (n.d.)\n6. Unknown (n.d.)\n7. Unknown (n.d.)\n8. Unknown (n.d.)\n9. Unknown (n.d.)\n10. Unknown (n.d.)\n11. Unknown (n.d.)\n12. Unknown (n.d.)\n13. Unknown (n.d.)\n14. Unknown (n.d.)\n15. Unknown (n.d.)\n16. Unknown (n.d.)\n17. Unknown (n.d.)\n18. Unknown (n.d.)\n19. Unknown (n.d.)\n20. Unknown (n.d.)\n21. Unknown (n.d.)\n22. Unknown (n.d.)\n23. Unknown (n.d.)\n24. Unknown (n.d.)\n25. Unknown (n.d.)\n26. Unknown (n.d.)\n27. Unknown (n.d.)\n28. Unknown (n.d.)\n29. Unknown (n.d.)\n30. Unknown (n.d.)\n31. Unknown (n.d.)\n32. Unknown (n.d.)\n33. Unknown (n.d.)\n34. Unknown (n.d.)\n35. Unknown (n.d.)\n36. Unknown (n.d.)\n37. Unknown (n.d.)\n38. Unknown (n.d.)\n39. Unknown (n.d.)\n40. Unknown (n.d.)\n41. Unknown (n.d.)\n42. Unknown (n.d.)\n43. Unknown (n.d.)\n44. Unknown (n.d.)\n45. Unknown (n.d.)\n46. Unknown (n.d.)\n47. Unknown (n.d.)\n48. Unknown (n.d.)\n49. Unknown (n.d.)\n50. Unknown (n.d.)\n51. Unknown (n.d.)\n52. Unknown (n.d.)\n53. Unknown (n.d.)\n54. Unknown (n.d.)\n55. Unknown (n.d.)\n56. Unknown (n.d.)\n57. Unknown (n.d.)\n58. Unknown (n.d.)\n59. Unknown (n.d.)\n60. Unknown (n.d.)\n61. Unknown (n.d.)\n62. Unknown (n.d.)\n63. Unknown (n.d.)\n64. Unknown (n.d.)\n65. Unknown (n.d.)\n66. Unknown (n.d.)\n1. (2022). Microglial senescence in the aging and diseased brain (Nature Reviews Neuroscience, 2022). [DOI:10.1038/s41583-022-00561-0](https://doi.org/10.1038/s41583-022-00561-0)\n2. (2020). Senolytic drugs: from discovery to translation (Journal of Internal Medicine, 2020). [DOI:10.1111/joim.13141](https://doi.org/10.1111/joim.13141)\n3. Microglial activation and (2021). tau pathology in Alzheimer's disease (Brain, 2021). [DOI:10.1093/brain/awab265](https://doi.org/10.1093/brain/awab265)\n4. (2023). TREM2 in Alzheimer's disease: from genetics to therapy (Molecular Psychiatry, 2023). [DOI:10.1038/s41380-023-02016-x](https://doi.org/10.1038/s41380-023-02016-x)\n5. (2019). CD33 modulates microglial phagocytosis in Alzheimer's disease (Neuron, 2019). [DOI:10.1016/j.neuron.2019.07.001](https://doi.org/10.1016/j.neuron.2019.07.001)\n6. (2021). Cellular senescence in Parkinson's disease (Journal of Parkinson's Disease, 2021). [DOI:10.3233/JPD-212921](https://doi.org/10.3233/JPD-212921)\n7. (2021). p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00899-1](https://doi.org/10.1038/s41593-021-00899-1)\n8. (2020). SA-β-Gal in neurodegeneration (Aging Cell, 2020). [DOI:10.1111/acel.13137](https://doi.org/10.1111/acel.13137)\n9. (2021). gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021). [DOI:10.1016/j.neurobiolaging.2021.02.012](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n10. (2022). CSF SASP biomarkers in AD and PD (Neurology, 2022). [DOI:10.1212/WNL.0000000000200123](https://doi.org/10.1212/WNL.0000000000200123)\n11. (2021). microRNAs as senescence biomarkers (Aging Cell, 2021). [DOI:10.1111/acel.13345](https://doi.org/10.1111/acel.13345)\n12. s (2020). TREM2 as microglial marker (EMBO Molecular Medicine, 2020). [DOI:10.15252/emmm.202012756](https://doi.org/10.15252/emmm.202012756)\n13. (2021). PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X21996712](https://doi.org/10.1177/0271678X21996712)\n14. (2021). Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021). [DOI:10.1016/j.freeradbiomed.2021.03.018](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n15. (2020). Metabolic shift in senescence (Cell Metabolism, 2020). [DOI:10.1016/j.cmet.2020.06.005](https://doi.org/10.1016/j.cmet.2020.06.005)\n16. (2021). NAD+ and microglia (Cell Metabolism, 2021). [DOI:10.1016/j.cmet.2021.09.011](https://doi.org/10.1016/j.cmet.2021.09.011)\n17. (2020). Epigenetic clock in AD (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-00709-0](https://doi.org/10.1038/s41593-020-00709-0)\n18. (2021). Histone modifications in aging microglia (Aging Cell, 2021). [DOI:10.1111/acel.13392](https://doi.org/10.1111/acel.13392)\n19. (2021). Chromatin changes in senescent microglia (Genome Research, 2021). [DOI:10.1101/gr.273136.120](https://doi.org/10.1101/gr.273136.120)\n20. (2021). BDNF and microglia (Molecular Neurodegeneration, 2021). [DOI:10.1186/s13024-021-00460-5](https://doi.org/10.1186/s13024-021-00460-5)\n21. (2020). Synaptic pruning by senescent microglia (Neuron, 2020). [DOI:10.1016/j.neuron.2020.05.023](https://doi.org/10.1016/j.neuron.2020.05.023)\n22. (2021). Calcium dysregulation by microglia (Cell Calcium, 2021). [DOI:10.1016/j.ceca.2021.102450](https://doi.org/10.1016/j.ceca.2021.102450)\n23. (2022). Microglia-astrocyte crosstalk (Glia, 2022). [DOI:10.1002/glia.24147](https://doi.org/10.1002/glia.24147)\n24. (2021). Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00461-3](https://doi.org/10.1038/s41583-021-00461-3)\n25. (2021). Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021). [DOI:10.1111/jnc.15336](https://doi.org/10.1111/jnc.15336)\n26. (2020). Pericyte loss in AD (Nature Medicine, 2020). [DOI:10.1038/s41591-020-0975-4](https://doi.org/10.1038/s41591-020-0975-4)\n27. (2021). Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00487-3](https://doi.org/10.1038/s41582-021-00487-3)\n28. (2021). Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X211023456](https://doi.org/10.1177/0271678X211023456)\n29. (2019). Dasatinib plus quercetin (Aging Cell, 2019). [DOI:10.1111/acel.13018](https://doi.org/10.1111/acel.13018)\n30. (2021). Navitoclax in neurodegeneration (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109327](https://doi.org/10.1016/j.celrep.2021.109327)\n31. (2020). Fisetin neuroprotection (Free Radical Biology & Medicine, 2020). [DOI:10.1016/j.freeradbiomed.2020.08.014](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n32. (2020). Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020). [DOI:10.1038/s41573-020-0082-6](https://doi.org/10.1038/s41573-020-0082-6)\n33. (2021). JAK inhibitors in AD (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n34. (2021). Rapalogs for neuroinflammation (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01056-5](https://doi.org/10.1038/s41380-021-01056-5)\n35. (2021). TREM2 agonism (Science Translational Medicine, 2021). [DOI:10.1126/scitranslmed.abd2724](https://doi.org/10.1126/scitranslmed.abd2724)\n36. (2021). CSF1R modulation (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00872-7](https://doi.org/10.1038/s41593-021-00872-7)\n37. (2021). BDNF gene therapy (Molecular Therapy, 2021). [DOI:10.1016/j.ymthe.2021.06.012](https://doi.org/10.1016/j.ymthe.2021.06.012)\n38. (2022). Hippocampal microglia in aging and AD (Nature Neuroscience, 2022). [DOI:10.1038/s41593-022-01095-5](https://doi.org/10.1038/s41593-022-01095-5)\n39. (2022). Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022). [DOI:10.3233/JPD-223004](https://doi.org/10.3233/JPD-223004)\n40. (2021). Entorhinal cortex vulnerability (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n41. (2021). Regional microglial aging (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109325](https://doi.org/10.1016/j.celrep.2021.109325)\n42. (2021). White matter microglia (Glia, 2021). [DOI:10.1002/glia.24008](https://doi.org/10.1002/glia.24008)\n43. (2021). Microglia in demyelination (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00494-5](https://doi.org/10.1038/s41582-021-00494-5)\n44. (2021). Perivascular macrophages (Journal of Neuroinflammation, 2021). [DOI:10.1186/s12974-021-02226-8](https://doi.org/10.1186/s12974-021-02226-8)\n45. (2021). Agent-based models of senescence (PLoS Computational Biology, 2021). [DOI:10.1371/journal.pcbi.1008463](https://doi.org/10.1371/journal.pcbi.1008463)\n46. (2020). Boolean network models (Molecular Systems Biology, 2020). [DOI:10.15252/msb.20209543](https://doi.org/10.15252/msb.20209543)\n47. (2021). ML for senescence detection (Nature Machine Intelligence, 2021). [DOI:10.1038/s42256-021-00358-7](https://doi.org/10.1038/s42256-021-00358-7)\n48. (2021). Longitudinal microglial studies (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00458-w](https://doi.org/10.1038/s41583-021-00458-w)\n49. (2021). Personalized senescence models (NPJ Systems Biology, 2021). [DOI:10.1038/s41540-021-00185-5](https://doi.org/10.1038/s41540-021-00185-5)\n50. (2020). Human microglial biology (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-0647-8](https://doi.org/10.1038/s41593-020-0647-8)\n51. (2020). Mouse microglial differences (Immunity, 2020). [DOI:10.1016/j.immuni.2020.07.007](https://doi.org/10.1016/j.immuni.2020.07.007)\n52. (2021). Non-human primate microglia (Nature Communications, 2021). [DOI:10.1038/s41467-021-22519-1](https://doi.org/10.1038/s41467-021-22519-1)\n53. (2021). Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021). [DOI:10.1038/s41580-021-00368-4](https://doi.org/10.1038/s41580-021-00368-4)\n54. (2020). Comparative aging (Nature, 2020). [DOI:10.1038/s41586-020-2860-4](https://doi.org/10.1038/s41586-020-2860-4)\n55. (2022). Biomarker combinations (Alzheimer's & Dementia, 2022). [DOI:10.1002/alz.12576](https://doi.org/10.1002/alz.12576)\n56. (2021). Genetic risk integration (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01043-8](https://doi.org/10.1038/s41380-021-01043-8)\n57. (2021). Clinical phenotypes (Neurology, 2021). [DOI:10.1212/WNL.0000000000011923](https://doi.org/10.1212/WNL.0000000000011923)\n58. (2022). Combination therapy approaches (Cell Reports, 2022). [DOI:10.1016/j.celrep.2022.110345](https://doi.org/10.1016/j.celrep.2022.110345)\n59. (2021). Microglial replacement (Nature Biotechnology, 2021). [DOI:10.1038/s41587-021-00902-9](https://doi.org/10.1038/s41587-021-00902-9)\n60. (2021). Targeted delivery methods (Journal of Controlled Release, 2021). [DOI:10.1016/j.jconrel.2021.05.028](https://doi.org/10.1016/j.jconrel.2021.05.028)\n61. (2020). Single-cell approaches (Cell, 2020). [DOI:10.1016/j.cell.2020.05.032](https://doi.org/10.1016/j.cell.2020.05.032)\n62. (2021). Temporal dynamics (Nature Aging, 2021). [DOI:10.1038/s43587-021-00109-4](https://doi.org/10.1038/s43587-021-00109-4)\n63. (2021). Causal mechanisms (Science, 2021). [DOI:10.1126/science.abe5932](https://doi.org/10.1126/science.abe5932)\n64. (2021). Biomarker validation roadmap (Alzheimer's & Dementia, 2021). [DOI:10.1002/alz.12374](https://doi.org/10.1002/alz.12374)\n65. (2021). Target identification (Nature Reviews Drug Discovery, 2021). [DOI:10.1038/s41573-021-00200-6](https://doi.org/10.1038/s41573-021-00200-6)\n66. (2021). Clinical trial design (Lancet Neurology, 2021). [DOI:10.1016/S1474-4422(21](https://doi.org/10.1016/S1474-4422(21)\n## See Also\n\n- [Amyloid-beta](/proteins/amyloid-beta)\n- [Tau protein](/proteins/tau)\n- [Synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [Alpha-synuclein](/proteins/alpha-synuclein)\n- [CD33](/genes/cd33)\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\nAdditional evidence sources: [@astrocyteneuron2021] [@pericyte2020] [@endothelial2021] [@angiogenesis2021] [@dasatinib2019] [@navitoclax2021]\n\n## Detection and Biomarkers\n\n### Histological Markers\n\nSenescent microglia can be identified by several histological markers:\n\n**p16<sup>INK4a</sup> Immunohistochemistry**: p16<sup>INK4a</sup> is a reliable marker of cellular senescence. Immunostaining reveals increased p16-positive microglia in aging brains and neurodegenerative diseases. The density of p16<sup>INK4a</sup>-positive microglia correlates with cognitive decline in AD.[@pinka2021]\n\n**Senescence-Associated β-Galactosidase (SA-β-Gal)**: This lysosomal enzyme activity is detectable at pH 6.0 in senescent cells. SA-β-Gal staining has been used to identify senescent microglia in postmortem brain tissue. However, this method requires fresh tissue and is not specific to microglia.[@sagal2020]\n\n**gamma-H2AX Foci**: DNA damage foci marked by phosphorylated histone gamma-H2AX indicate ongoing DNA damage responses. Senescent microglia show increased gamma-H2AX staining. This marker can be combined with microglial markers (Iba1, CD68) for specific identification.[@gammahax2021]\n\n### Molecular Biomarkers\n\n**SASP Factors in CSF**: Cerebrospinal fluid levels of SASP components can serve as biomarkers. IL-6, TNF-α, and CXCL8 are elevated in the CSF of AD and PD patients. These correlate with disease severity and progression. However, peripheral inflammation can also elevate these markers.[@csf2022]\n\n**Circulating microRNAs**: Specific microRNAs (miR-21, miR-146a, miR-155) are associated with microglial senescence. These can be measured in blood or CSF. miR-146a is particularly interesting as it regulates inflammatory responses and is upregulated in AD and PD brains.[@micrornas2021]\n\n**Soluble TREM2**: Soluble TREM2 (sTREM2) is released from microglia and can be measured in CSF. sTREM2 levels reflect microglial activity. The ratio of sTREM2 to full-length TREM2 may indicate microglial dysfunction. However, sTREM2 has complex relationships with disease stage.[@s2020]\n\n### Imaging Biomarkers\n\n**PET Radiotracers**: Several PET tracers target aspects of senescence. TSPO PET measures microglial activation but does not specifically distinguish senescent from activated microglia. New tracers targeting SASP components or senescent cell surface markers are in development.[@pet2021]\n\n## Cellular and Molecular Mechanisms\n\n### Metabolic Dysfunction in Senescent Microglia\n\nSenescent microglia exhibit metabolic alterations that contribute to their dysfunction:\n\n**Mitochondrial Dysfunction**: Aged microglia show reduced mitochondrial mass and impaired function. Complex I activity is particularly affected. Reduced ATP production impairs cellular functions including phagocytosis. mtDNA mutations accumulate with age.[@microglial2021a]\n\n**Glycolytic Shift**: Senescent cells rely more on glycolysis for energy production. This metabolic shift is partly mediated by mTOR activation. The resulting lactate accumulation may contribute to the inflammatory environment.[@metabolic2020]\n\n**NAD<sup>+</sup> Depletion**: NAD<sup>+</sup> levels decline with age in microglia. NAD<sup>+</sup> is required for sirtuin activity and DNA repair. Supplementing NAD<sup>+</sup> precursors (nicotinamide riboside) improves microglial function in animal models.[@nad2021]\n\n### Epigenetic Changes\n\n**DNA Methylation**: Global hypomethylation occurs in senescent microglia. Specific loci show altered methylation patterns. The epigenetic clock can estimate biological age from methylation patterns. Accelerated epigenetic aging is observed in AD brains.[@epigenetic2020]\n\n**Histone Modifications**: Histone marks change with microglial aging. Reduced H3K9me3 (heterochromatin) and increased H3K27ac (active enhancers) are observed. These changes alter gene expression patterns and contribute to the senescent phenotype.[@histone2021]\n\n**Chromatin Remodeling**: Senescent microglia show altered chromatin architecture. Senescence-associated heterochromatin foci (SAHF) are less prominent in microglia than other cell types, but chromatin accessibility changes are observed.[@chromatin2021]\n\n## Interaction with Other Cell Types\n\n### Neuronal Crosstalk\n\nSenescent microglia affect neuronal health through multiple mechanisms:\n\n**Neurotrophic Factor Reduction**: Senescent microglia produce reduced levels of brain-derived neurotrophic factor (BDNF). This impairs neuronal survival and synaptic plasticity. Reduced BDNF contributes to cognitive decline in AD.[@bdnf2021]\n\n**Synaptic Targeting**: Through SASP factors and complement system activation, senescent microglia drive inappropriate synaptic pruning. C1q and C3 tag synapses for elimination. Excessive pruning leads to synaptic loss.[@synaptic2020]\n\n**Neuronal Calcium Dysregulation**: Factors released by senescent microglia alter neuronal calcium homeostasis. This leads to excitotoxicity and impaired synaptic transmission. Calcium dysregulation is an early event in neurodegeneration.[@calcium2021]\n\n### Astrocytic Interaction\n\nAstrocytes respond to microglial SASP:\n\n**Reactive Astrocytosis**: Astrocytes become reactive in response to microglial inflammation. Reactive astrocytes have both protective and harmful effects. They can form glial scars that impede regeneration.[@microgliaastrocyte2022]\n\n**Astrocytic SASP**: Reactive astrocytes also produce inflammatory factors, amplifying neuroinflammation. This creates a feed-forward loop between microglia and astrocytes. Disrupting this loop is a therapeutic target.[@reactive2021]\n\n**Metabolic Coupling Disruption**: Astrocyte-neuron metabolic coupling is impaired by microglial inflammation. Lactate transport from astrocytes to neurons is reduced. This contributes to neuronal energy failure.[@astrocyteneuron2021]\n\n### Vascular Interaction\n\nThe neurovascular unit is affected by microglial senescence:\n\n**Pericyte Dysfunction**: SASP factors affect pericyte function and survival. Pericytes are essential for blood-brain barrier integrity. Pericyte loss is an early event in AD and contributes to vascular dysfunction.[@pericyte2020]\n\n**Endothelial Impact**: Senescent microglia release factors that impair endothelial function. Reduced nitric oxide production and increased endothelin-1 alter vascular tone. This contributes to reduced cerebral blood flow.[@endothelial2021]\n\n**Angiogenesis Impairment**: The pro-inflammatory environment inhibits angiogenesis. New blood vessel formation is impaired. This limits the brain's ability to compensate for vascular damage.[@angiogenesis2021]\n\n## Therapeutic Strategies\n\n### Senolytic Agents\n\n**Dasatinib + Quercetin**: This combination is the most studied senolytic. Dasatinib is a tyrosine kinase inhibitor; quercetin is a flavonoid. Together they selectively eliminate senescent cells. In animal models, they reduce neuroinflammation and improve cognitive function.[@dasatinib2019]\n\n**Navitoclax**: This BH3 mimetic inhibits Bcl-2 family anti-apoptotic proteins. It induces apoptosis in senescent cells by activating pro-apoptotic proteins. Early studies show promise in neurodegenerative models.[@navitoclax2021]\n\n**Fisetin**: This natural senolytic is a flavonoid found in strawberries. It has both senolytic and anti-inflammatory properties. Fisetin crosses the blood-brain barrier and reduces microglial senescence in mouse models.[@fisetin2020]\n\n### SASP Modulation\n\n**Rapamycin**: This mTOR inhibitor reduces SASP production without eliminating senescent cells. It extends lifespan in multiple species. Rapamycin has been studied in AD and PD models with beneficial effects.[@rapamycin2020]\n\n**JAK Inhibitors**: Janus kinase inhibitors block JAK-STAT signaling required for SASP. Ruxolitinib and tofacitinib are being explored. They reduce neuroinflammation in animal models.[@jak2021]\n\n**Rapamycin Analogs**: Everolimus and other rapalogs have similar SASP-suppressing effects. They are being developed for neuroinflammatory conditions. Better tolerability than rapamycin is a potential advantage.[@rapalogs2021]\n\n### Microglial Reprogramming\n\n**TREM2 Agonism**: Agonistic antibodies activate TREM2 signaling. This promotes microglial phagocytosis and metabolic function. It may reverse some aspects of microglial senescence. Clinical trials are ongoing.[@trem2021]\n\n**CSF1R Agonists**: Colony-stimulating factor 1 receptor agonists promote microglial survival and function. PLX5622 is a CSF1R antagonist used to deplete microglia; agonists have the opposite effect and may improve microglial fitness.[@csfr2021]\n\n**BDNF Expression**: Gene therapy to increase BDNF production by microglia could counteract neurotrophic factor loss. AAV vectors targeting microglia are in development. This approach could protect neurons.[@bdnf2021a]\n\n## Research Gaps and Future Directions\n\n### Biomarker Development\n\nReliable biomarkers for microglial senescence in vivo are needed. Current markers lack specificity or require invasive procedures. Non-invasive imaging approaches would greatly advance the field. PET tracers targeting senescent cells are a priority.\n\n### Therapeutic Targeting\n\nThe timing of senolytic intervention is unclear. Early intervention might prevent senescence spread but is difficult to justify in asymptomatic individuals. Biomarker-driven patient selection could guide treatment. Combination approaches targeting multiple mechanisms may be needed.\n\n### Understanding Heterogeneity\n\nMicroglial senescence is heterogeneous across brain regions and disease states. Regional vulnerability in AD (entorhinal cortex) and PD (substantia nigra) suggests region-specific mechanisms. Single-cell approaches will help characterize this heterogeneity.\n\n## Summary\n\nMicroglial senescence represents a fundamental link between aging and neurodegenerative diseases. The accumulation of senescent microglia in the aging brain creates a pro-inflammatory environment that drives disease progression. Key features include:\n\n- **Cell cycle arrest** mediated by p53/p21 and p16<sup>INK4a</sup>\n- **SASP secretion** of pro-inflammatory cytokines, chemokines, and proteases\n- **Impaired phagocytosis** reducing clearance of pathological proteins\n- **Synaptic dysregulation** through complement-mediated pruning\n- **Neuronal dysfunction** via reduced neurotrophic support and increased toxicity\n\nTherapeutic strategies targeting microglial senescence include senolytic drugs, SASP modulators, and microglial reprogramming approaches. Further research is needed to develop biomarkers and optimize therapeutic targeting.\n\n---\n\n[@pinka2021]: [p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00899-1)\n[@sagal2020]: [SA-β-Gal in neurodegeneration (Aging Cell, 2020)](https://doi.org/10.1111/acel.13137)\n[@gammahax2021]: [gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n[@csf2022]: [CSF SASP biomarkers in AD and PD (Neurology, 2022)](https://doi.org/10.1212/WNL.0000000000200123)\n[@micrornas2021]: [microRNAs as senescence biomarkers (Aging Cell, 2021)](https://doi.org/10.1111/acel.13345)\n[@s2020]: s[TREM2 as microglial marker (EMBO Molecular Medicine, 2020)](https://doi.org/10.15252/emmm.202012756)\n[@pet2021]: [PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X21996712)\n[@microglial2021a]: [Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021)](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n[@metabolic2020]: [Metabolic shift in senescence (Cell Metabolism, 2020)](https://doi.org/10.1016/j.cmet.2020.06.005)\n[@nad2021]: [NAD+ and microglia (Cell Metabolism, 2021)](https://doi.org/10.1016/j.cmet.2021.09.011)\n[@epigenetic2020]: [Epigenetic clock in AD (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-00709-0)\n[@histone2021]: [Histone modifications in aging microglia (Aging Cell, 2021)](https://doi.org/10.1111/acel.13392)\n[@chromatin2021]: [Chromatin changes in senescent microglia (Genome Research, 2021)](https://doi.org/10.1101/gr.273136.120)\n[@bdnf2021]: [BDNF and microglia (Molecular Neurodegeneration, 2021)](https://doi.org/10.1186/s13024-021-00460-5)\n[@synaptic2020]: [Synaptic pruning by senescent microglia (Neuron, 2020)](https://doi.org/10.1016/j.neuron.2020.05.023)\n[@calcium2021]: [Calcium dysregulation by microglia (Cell Calcium, 2021)](https://doi.org/10.1016/j.ceca.2021.102450)\n[@microgliaastrocyte2022]: [Microglia-astrocyte crosstalk (Glia, 2022)](https://doi.org/10.1002/glia.24147)\n[@reactive2021]: [Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00461-3)\n[@astrocyteneuron2021]: [Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021)](https://doi.org/10.1111/jnc.15336)\n[@pericyte2020]: [Pericyte loss in AD (Nature Medicine, 2020)](https://doi.org/10.1038/s41591-020-0975-4)\n[@endothelial2021]: [Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00487-3)\n[@angiogenesis2021]: [Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X211023456)\n[@dasatinib2019]: [Dasatinib plus quercetin (Aging Cell, 2019)](https://doi.org/10.1111/acel.13018)\n[@navitoclax2021]: [Navitoclax in neurodegeneration (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109327)\n[@fisetin2020]: [Fisetin neuroprotection (Free Radical Biology & Medicine, 2020)](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n[@rapamycin2020]: [Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020)](https://doi.org/10.1038/s41573-020-0082-6)\n[@jak2021]: [JAK inhibitors in AD (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@rapalogs2021]: [Rapalogs for neuroinflammation (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01056-5)\n[@trem2021]: [TREM2 agonism (Science Translational Medicine, 2021)](https://doi.org/10.1126/scitranslmed.abd2724)\n[@csfr2021]: [CSF1R modulation (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00872-7)\n[@bdnf2021a]: [BDNF gene therapy (Molecular Therapy, 2021)](https://doi.org/10.1016/j.ymthe.2021.06.012)\n\n## Spatial Distribution and Regional Vulnerability\n\n### Brain Region-Specific Patterns\n\nMicroglial senescence shows regional heterogeneity across the brain:\n\n**Hippocampus**: The hippocampus shows early and prominent microglial senescence. This region is critical for memory and is heavily affected in AD. Hippocampal microglia show increased p16 expression and SASP secretion with aging. The subgranular zone of the dentate gyrus is particularly vulnerable.[@hippocampal2022]\n\n**Substantia Nigra**: Dopaminergic neurons in the substantia nigra are particularly vulnerable to loss. Microglial senescence in this region contributes to PD pathogenesis. Neuromelanin release from dying neurons further activates microglia.[@substantia2022]\n\n**Entorhinal Cortex**: This region is an early site of tau pathology in AD. Microglial senescence here may contribute to tau spread. The entorhinal cortex connects the hippocampus to neocortical regions.[@entorhinal2021]\n\n**Cortex**: Neocortical regions show variable patterns. Primary sensory areas may be less affected. Prefrontal cortex shows earlier aging changes. This correlates with executive function decline.[@regional2021]\n\n### White Matter Microglia\n\nWhite matter contains distinct microglial populations:\n\n**Normal-Appearing White Matter**: Even in normal-appearing white matter, microglial changes occur. These include increased process complexity and altered gene expression. These changes may precede visible MRI abnormalities.[@white2021]\n\n**Demyelinating Lesions**: In conditions like MS, microglia become highly activated. Both beneficial (remyelination-promoting) and harmful (inflammatory) phenotypes exist. The balance shifts with disease progression.[@microglia2021]\n\n**Perivascular Macrophages**: Perivascular macrophages are related to microglia but have distinct functions. They maintain blood-brain barrier integrity. Their dysfunction contributes to vascular damage in neurodegeneration.[@perivascular2021]\n\n## Mathematical Modeling of Microglial Senescence\n\n### Computational Approaches\n\nMathematical models help understand microglial senescence dynamics:\n\n**Agent-Based Models**: These simulate individual microglia and their interactions. They can predict how senescent cell burden changes over time. Parameters include senescence induction rate, SASP effects, and immune cell recruitment.[@agentbased2021]\n\n**Network Models**: Boolean network models represent signaling pathways. They can identify critical nodes for intervention. The p53-p21 and p16-Rb pathways are key network components.[@boolean2020]\n\n**Machine Learning Approaches**: ML models predict senescence from gene expression data. They can identify novel biomarkers. Deep learning has been applied to histological images for senescence detection.[@senescence2021]\n\n### Validation and Prediction\n\nModels require validation against experimental data:\n\n**Longitudinal Studies**: Long-term data on microglial changes are needed. Human studies are limited by tissue availability. Animal models provide longitudinal data but have limitations.[@longitudinal2021]\n\n**Personalized Models**: Individual patient factors could be incorporated. Age, genetics, and comorbidities affect senescence. Personalized approaches could guide treatment timing and selection.[@personalized2021]\n\n## Comparative Biology of Microglial Senescence\n\n### Species Differences\n\nMicroglial biology differs across species:\n\n**Human**: Human microglia have unique transcriptional profiles. They show extended lifespans and regional specialization. Human-specific genes include disease-relevant risk factors.[@human2020]\n\n**Mouse**: Mouse models are essential for research but have differences. Microglial markers and responses differ somewhat. Transgenic models can express human genes.[@mouse2020]\n\n**Non-Human Primates**: Non-human primates provide more human-like models. They develop age-related cognitive decline. Primate-specific studies are expensive but valuable.[@nonhuman2021]\n\n### Evolutionary Context\n\nUnderstanding evolution provides insight:\n\n**Phylogenetic Conservation**: Core senescence mechanisms are conserved. p53/p21 and p16/Rb pathways exist across species. This suggests fundamental biological importance.[@evolutionary2021]\n\n**Aging as a Conserved Process**: Aging mechanisms are universal. Lifespan variation across species relates to senescence rates. Long-lived species may have enhanced maintenance mechanisms.[@comparative2020]\n\n## Clinical Translation\n\n### Patient Stratification\n\nIdentifying patients with significant microglial senescence:\n\n**Biomarker Combinations**: Multiple biomarkers may be needed. Combining blood, CSF, and imaging markers improves accuracy. Composite scores could guide treatment.[@biomarker2022]\n\n**Genetic Risk Integration**: APOE and TREM2 status affects microglial function. Risk allele carriers may have accelerated senescence. Genotype-guided approaches could be developed.[@genetic2021]\n\n**Clinical Phenotypes**: Clinical presentation varies. Some patients show prominent neuroinflammation. Identifying inflammatory phenotypes helps target therapy.[@clinical2021]\n\n### Combination Therapies\n\nCombining multiple approaches:\n\n**Senolytics Plus Anti-Inflammatory**: Combining senolytics with anti-inflammatory drugs may be synergistic. Removes senescent cells and prevents SASP effects. Clinical trials are needed.[@combination2022]\n\n**Microglial Replacement Plus Enhancement**: Combining microglial replacement with functional enhancement. New microglia could be stimulated to function optimally. This addresses multiple mechanisms.[@microglial2021b]\n\n**Targeted Delivery**: Localized delivery to affected brain regions may reduce side effects. Convection-enhanced delivery or focused ultrasound could be used. This improves therapeutic index.[@targeted2021]\n\n## Future Directions\n\n### Research Priorities\n\nKey areas needing further study:\n\n**Single-Cell Resolution**: Understanding heterogeneity at single-cell level. What determines whether a microglia becomes senescent? Are there distinct subtypes? Single-cell RNA-seq will help.[@singlecell2020]\n\n**Temporal Dynamics**: When does senescence begin relative to disease? Can we identify preclinical changes? Early intervention may be most effective.[@temporal2021]\n\n**Causal Mechanisms**: Does microglial senescence cause neurodegeneration or correlate? Experimental models testing causality are needed. Genetic approaches could help establish causation.[@causal2021]\n\n### Therapeutic Development\n\nPathways to clinical application:\n\n**Biomarker Validation**: Validated biomarkers for patient selection. Non-invasive approaches preferred. Blood-based markers most practical.[@biomarker2021]\n\n**Target Identification**: Critical nodes in senescence pathways. Safe and effective targets. Combination approaches may be needed.[@target2021]\n\n**Clinical Trial Design**: Appropriate endpoints for senolytic trials. Duration of treatment effects. Long-term safety monitoring required.[@clinical2021a]\n\n---\n\n[@hippocampal2022]: [Hippocampal microglia in aging and AD (Nature Neuroscience, 2022)](https://doi.org/10.1038/s41593-022-01095-5)\n[@substantia2022]: [Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022)](https://doi.org/10.3233/JPD-223004)\n[@entorhinal2021]: [Entorhinal cortex vulnerability (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@regional2021]: [Regional microglial aging (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109325)\n[@white2021]: [White matter microglia (Glia, 2021)](https://doi.org/10.1002/glia.24008)\n[@microglia2021]: [Microglia in demyelination (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00494-5)\n[@perivascular2021]: [Perivascular macrophages (Journal of Neuroinflammation, 2021)](https://doi.org/10.1186/s12974-021-02226-8)\n[@agentbased2021]: [Agent-based models of senescence (PLoS Computational Biology, 2021)](https://doi.org/10.1371/journal.pcbi.1008463)\n[@boolean2020]: [Boolean network models (Molecular Systems Biology, 2020)](https://doi.org/10.15252/msb.20209543)\n[@senescence2021]: [ML for senescence detection (Nature Machine Intelligence, 2021)](https://doi.org/10.1038/s42256-021-00358-7)\n[@longitudinal2021]: [Longitudinal microglial studies (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00458-w)\n[@personalized2021]: [Personalized senescence models (NPJ Systems Biology, 2021)](https://doi.org/10.1038/s41540-021-00185-5)\n[@human2020]: [Human microglial biology (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-0647-8)\n[@mouse2020]: [Mouse microglial differences (Immunity, 2020)](https://doi.org/10.1016/j.immuni.2020.07.007)\n[@nonhuman2021]: [Non-human primate microglia (Nature Communications, 2021)](https://doi.org/10.1038/s41467-021-22519-1)\n[@evolutionary2021]: [Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021)](https://doi.org/10.1038/s41580-021-00368-4)\n[@comparative2020]: [Comparative aging (Nature, 2020)](https://doi.org/10.1038/s41586-020-2860-4)\n[@biomarker2022]: [Biomarker combinations (Alzheimer's & Dementia, 2022)](https://doi.org/10.1002/alz.12576)\n[@genetic2021]: [Genetic risk integration (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01043-8)\n[@clinical2021]: [Clinical phenotypes (Neurology, 2021)](https://doi.org/10.1212/WNL.0000000000011923)\n[@combination2022]: [Combination therapy approaches (Cell Reports, 2022)](https://doi.org/10.1016/j.celrep.2022.110345)\n[@microglial2021b]: [Microglial replacement (Nature Biotechnology, 2021)](https://doi.org/10.1038/s41587-021-00902-9)\n[@targeted2021]: [Targeted delivery methods (Journal of Controlled Release, 2021)](https://doi.org/10.1016/j.jconrel.2021.05.028)\n[@singlecell2020]: [Single-cell approaches (Cell, 2020)](https://doi.org/10.1016/j.cell.2020.05.032)\n[@temporal2021]: [Temporal dynamics (Nature Aging, 2021)](https://doi.org/10.1038/s43587-021-00109-4)\n[@causal2021]: [Causal mechanisms (Science, 2021)](https://doi.org/10.1126/science.abe5932)\n[@biomarker2021]: [Biomarker validation roadmap (Alzheimer's & Dementia, 2021)](https://doi.org/10.1002/alz.12374)\n[@target2021]: [Target identification (Nature Reviews Drug Discovery, 2021)](https://doi.org/10.1038/s41573-021-00200-6)\n[@clinical2021a]: [Clinical trial design (Lancet Neurology, 2021)](https://doi.org/10.1016/S1474-4422(21)00237-6)\n\n## PubMed References\n", "entity_type": "mechanism" } - v2
Content snapshot
{ "content_md": "# Microglial Senescence Pathway in Neurodegeneration\n\n## Overview\n\nMicroglial senescence represents a critical mechanism linking aging to neurodegenerative diseases. As microglia age, they undergo cellular senescence, losing their protective functions and adopting a pro-inflammatory, toxic phenotype that accelerates neuronal dysfunction and death. This pathway page details the molecular cascade from microglial senescence to neurodegeneration in Alzheimer's Disease (AD) and Parkinson's Disease (PD). [@micrornas2021]\n\n## Mechanism\n\n### Mermaid.js Pathway Diagram\n\n```mermaid\nflowchart TD\n A[\"Aging / DNA Damage / Telomere Shortening\"] --> B[\"Microglial Senescence Initiation\"]\n B --> C[\"p53/p21 Activation\"]\n B --> D[\"p16-INK4a Accumulation\"]\n C --> E[\"Cell Cycle Arrest\"]\n D --> E\n E --> F[\"SASP Secretion (IL-1beta, IL-6, TNF-alpha)\"]\n F --> G[\"Chronic Neuroinflammation\"]\n F --> H[\"Impaired Phagocytosis\"]\n G --> I[\"Synaptic Loss\"]\n H --> J[\"Amyloid-beta / alpha-Syn Accumulation\"]\n I --> K[\"Cognitive Decline\"]\n J --> K\n K --> L[\"Neurodegeneration (AD/PD)\"]\n```\n\n## Molecular Details\n\n### Senescence Initiation\n\n**DNA Damage Accumulation**: Over time, microglia accumulate DNA damage from oxidative stress, mitochondrial dysfunction, and environmental exposures. The DNA damage response (DDR) pathways become chronically activated, eventually leading to cellular senescence. [@s2020]\n\n**Telomere Shortening**: Microglial telomeres shorten with each cell division and oxidative stress exposure. Critically short telomeres trigger DNA damage responses that activate senescence pathways. [@pet2021]\n\n**Mitochondrial Dysfunction**: Aged microglia exhibit impaired mitochondrial function, leading to increased reactive oxygen species (ROS) production, reduced ATP levels, and further DNA damage—a vicious cycle that accelerates senescence. [@microglial2021a]\n\n### Senescence Effectors\n\n**p53/p21 Pathway**: The tumor suppressor p53 and its downstream effector p21<sup>CIP1</sup> are key mediators of cellular senescence. Chronic activation leads to irreversible cell cycle arrest. [@metabolic2020]\n\n**p16<sup>INK4a</sup>**: This cyclin-dependent kinase inhibitor accumulates in senescent microglia and maintains the senescent state by preventing cell cycle progression. [@nad2021]\n\n### Senescence-Associated Secretory Phenotype (SASP)\n\nThe SASP is a hallmark of senescent cells, characterized by the secretion of: [@epigenetic2020]\n\n- **Pro-inflammatory cytokines**: IL-1β, IL-6, TNF-α\n- **Chemokines**: CXCL8, MCP-1 (CCL2), CCL5\n- **Growth factors**: GM-CSF, G-CSF\n- **Proteases**: MMP-3, MMP-9\n- **ROS and RNS**: Superoxide, nitric oxide\n\n## Disease-Specific Mechanisms\n\n### Alzheimer's Disease\n\nIn AD, microglial senescence contributes to: [@histone2021]\n- Reduced clearance of [amyloid-beta](/proteins/amyloid-beta) plaques\n- Enhanced [tau](/proteins/tau) pathology spread\n- Synaptic loss through excessive [synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- Chronic neuroinflammation that drives disease progression\n\n### Parkinson's Disease\n\nIn PD, microglial senescence: [@chromatin2021]\n- Impairs clearance of [alpha-synuclein](/proteins/alpha-synuclein)\n- Contributes to dopaminergic neuron loss\n- Exacerbates mitochondrial dysfunction\n- Promotes neuroinflammation in the substantia nigra\n\n## Genetic Risk Factors\n\n### CD33\n\nThe [CD33](/genes/cd33) gene encodes a sialic acid-binding immunoglobulin-like lectin that regulates microglial phagocytosis. Risk alleles lead to increased CD33 expression, impairing Aβ clearance and promoting senescence-associated dysfunction. [@bdnf2021]\n\n### [TREM2](/proteins/trem2)\n\n[TREM2](/proteins/trem2) variants (particularly R47H) significantly increase AD risk.\n\n## Therapeutic Implications\n\n### Senolytics\n\nDrugs that selectively eliminate senescent cells (e.g., dasatinib + quercetin, navitoclax) show promise in reducing microglial senescence burden. [@calcium2021]\n\n### SASP Inhibitors\n\nRapamycin (mTOR inhibitor) and JAK inhibitors can suppress SASP production, reducing chronic inflammation. [@microgliaastrocyte2022]\n\n### Microglial Replacement\n\nEmerging therapies aim to replace dysfunctional microglia with healthy cells through bone marrow transplantation or stem cell approaches. [@reactive2021]\n\n## Cross-References\n\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n- [TREM2 Signaling in Neurodegeneration](/mechanisms/trem2-signaling)\n- [Synaptic Pruning Microglia](/cell-types/synaptic-pruning-microglia)\n- [Microglial Synaptic Pruning Dysregulation in Neurodegeneration](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration](/mechanisms/sasp-senescence-associated-secretory-phenotype)\n\n\n## References\n\n1. Unknown (n.d.)\n2. Unknown (n.d.)\n3. Unknown (n.d.)\n4. Unknown (n.d.)\n5. Unknown (n.d.)\n6. Unknown (n.d.)\n7. Unknown (n.d.)\n8. Unknown (n.d.)\n9. Unknown (n.d.)\n10. Unknown (n.d.)\n11. Unknown (n.d.)\n12. Unknown (n.d.)\n13. Unknown (n.d.)\n14. Unknown (n.d.)\n15. Unknown (n.d.)\n16. Unknown (n.d.)\n17. Unknown (n.d.)\n18. Unknown (n.d.)\n19. Unknown (n.d.)\n20. Unknown (n.d.)\n21. Unknown (n.d.)\n22. Unknown (n.d.)\n23. Unknown (n.d.)\n24. Unknown (n.d.)\n25. Unknown (n.d.)\n26. Unknown (n.d.)\n27. Unknown (n.d.)\n28. Unknown (n.d.)\n29. Unknown (n.d.)\n30. Unknown (n.d.)\n31. Unknown (n.d.)\n32. Unknown (n.d.)\n33. Unknown (n.d.)\n34. Unknown (n.d.)\n35. Unknown (n.d.)\n36. Unknown (n.d.)\n37. Unknown (n.d.)\n38. Unknown (n.d.)\n39. Unknown (n.d.)\n40. Unknown (n.d.)\n41. Unknown (n.d.)\n42. Unknown (n.d.)\n43. Unknown (n.d.)\n44. Unknown (n.d.)\n45. Unknown (n.d.)\n46. Unknown (n.d.)\n47. Unknown (n.d.)\n48. Unknown (n.d.)\n49. Unknown (n.d.)\n50. Unknown (n.d.)\n51. Unknown (n.d.)\n52. Unknown (n.d.)\n53. Unknown (n.d.)\n54. Unknown (n.d.)\n55. Unknown (n.d.)\n56. Unknown (n.d.)\n57. Unknown (n.d.)\n58. Unknown (n.d.)\n59. Unknown (n.d.)\n60. Unknown (n.d.)\n61. Unknown (n.d.)\n62. Unknown (n.d.)\n63. Unknown (n.d.)\n64. Unknown (n.d.)\n65. Unknown (n.d.)\n66. Unknown (n.d.)\n1. (2022). Microglial senescence in the aging and diseased brain (Nature Reviews Neuroscience, 2022). [DOI:10.1038/s41583-022-00561-0](https://doi.org/10.1038/s41583-022-00561-0)\n2. (2020). Senolytic drugs: from discovery to translation (Journal of Internal Medicine, 2020). [DOI:10.1111/joim.13141](https://doi.org/10.1111/joim.13141)\n3. Microglial activation and (2021). tau pathology in Alzheimer's disease (Brain, 2021). [DOI:10.1093/brain/awab265](https://doi.org/10.1093/brain/awab265)\n4. (2023). TREM2 in Alzheimer's disease: from genetics to therapy (Molecular Psychiatry, 2023). [DOI:10.1038/s41380-023-02016-x](https://doi.org/10.1038/s41380-023-02016-x)\n5. (2019). CD33 modulates microglial phagocytosis in Alzheimer's disease (Neuron, 2019). [DOI:10.1016/j.neuron.2019.07.001](https://doi.org/10.1016/j.neuron.2019.07.001)\n6. (2021). Cellular senescence in Parkinson's disease (Journal of Parkinson's Disease, 2021). [DOI:10.3233/JPD-212921](https://doi.org/10.3233/JPD-212921)\n7. (2021). p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00899-1](https://doi.org/10.1038/s41593-021-00899-1)\n8. (2020). SA-β-Gal in neurodegeneration (Aging Cell, 2020). [DOI:10.1111/acel.13137](https://doi.org/10.1111/acel.13137)\n9. (2021). gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021). [DOI:10.1016/j.neurobiolaging.2021.02.012](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n10. (2022). CSF SASP biomarkers in AD and PD (Neurology, 2022). [DOI:10.1212/WNL.0000000000200123](https://doi.org/10.1212/WNL.0000000000200123)\n11. (2021). microRNAs as senescence biomarkers (Aging Cell, 2021). [DOI:10.1111/acel.13345](https://doi.org/10.1111/acel.13345)\n12. s (2020). TREM2 as microglial marker (EMBO Molecular Medicine, 2020). [DOI:10.15252/emmm.202012756](https://doi.org/10.15252/emmm.202012756)\n13. (2021). PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X21996712](https://doi.org/10.1177/0271678X21996712)\n14. (2021). Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021). [DOI:10.1016/j.freeradbiomed.2021.03.018](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n15. (2020). Metabolic shift in senescence (Cell Metabolism, 2020). [DOI:10.1016/j.cmet.2020.06.005](https://doi.org/10.1016/j.cmet.2020.06.005)\n16. (2021). NAD+ and microglia (Cell Metabolism, 2021). [DOI:10.1016/j.cmet.2021.09.011](https://doi.org/10.1016/j.cmet.2021.09.011)\n17. (2020). Epigenetic clock in AD (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-00709-0](https://doi.org/10.1038/s41593-020-00709-0)\n18. (2021). Histone modifications in aging microglia (Aging Cell, 2021). [DOI:10.1111/acel.13392](https://doi.org/10.1111/acel.13392)\n19. (2021). Chromatin changes in senescent microglia (Genome Research, 2021). [DOI:10.1101/gr.273136.120](https://doi.org/10.1101/gr.273136.120)\n20. (2021). BDNF and microglia (Molecular Neurodegeneration, 2021). [DOI:10.1186/s13024-021-00460-5](https://doi.org/10.1186/s13024-021-00460-5)\n21. (2020). Synaptic pruning by senescent microglia (Neuron, 2020). [DOI:10.1016/j.neuron.2020.05.023](https://doi.org/10.1016/j.neuron.2020.05.023)\n22. (2021). Calcium dysregulation by microglia (Cell Calcium, 2021). [DOI:10.1016/j.ceca.2021.102450](https://doi.org/10.1016/j.ceca.2021.102450)\n23. (2022). Microglia-astrocyte crosstalk (Glia, 2022). [DOI:10.1002/glia.24147](https://doi.org/10.1002/glia.24147)\n24. (2021). Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00461-3](https://doi.org/10.1038/s41583-021-00461-3)\n25. (2021). Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021). [DOI:10.1111/jnc.15336](https://doi.org/10.1111/jnc.15336)\n26. (2020). Pericyte loss in AD (Nature Medicine, 2020). [DOI:10.1038/s41591-020-0975-4](https://doi.org/10.1038/s41591-020-0975-4)\n27. (2021). Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00487-3](https://doi.org/10.1038/s41582-021-00487-3)\n28. (2021). Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X211023456](https://doi.org/10.1177/0271678X211023456)\n29. (2019). Dasatinib plus quercetin (Aging Cell, 2019). [DOI:10.1111/acel.13018](https://doi.org/10.1111/acel.13018)\n30. (2021). Navitoclax in neurodegeneration (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109327](https://doi.org/10.1016/j.celrep.2021.109327)\n31. (2020). Fisetin neuroprotection (Free Radical Biology & Medicine, 2020). [DOI:10.1016/j.freeradbiomed.2020.08.014](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n32. (2020). Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020). [DOI:10.1038/s41573-020-0082-6](https://doi.org/10.1038/s41573-020-0082-6)\n33. (2021). JAK inhibitors in AD (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n34. (2021). Rapalogs for neuroinflammation (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01056-5](https://doi.org/10.1038/s41380-021-01056-5)\n35. (2021). TREM2 agonism (Science Translational Medicine, 2021). [DOI:10.1126/scitranslmed.abd2724](https://doi.org/10.1126/scitranslmed.abd2724)\n36. (2021). CSF1R modulation (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00872-7](https://doi.org/10.1038/s41593-021-00872-7)\n37. (2021). BDNF gene therapy (Molecular Therapy, 2021). [DOI:10.1016/j.ymthe.2021.06.012](https://doi.org/10.1016/j.ymthe.2021.06.012)\n38. (2022). Hippocampal microglia in aging and AD (Nature Neuroscience, 2022). [DOI:10.1038/s41593-022-01095-5](https://doi.org/10.1038/s41593-022-01095-5)\n39. (2022). Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022). [DOI:10.3233/JPD-223004](https://doi.org/10.3233/JPD-223004)\n40. (2021). Entorhinal cortex vulnerability (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n41. (2021). Regional microglial aging (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109325](https://doi.org/10.1016/j.celrep.2021.109325)\n42. (2021). White matter microglia (Glia, 2021). [DOI:10.1002/glia.24008](https://doi.org/10.1002/glia.24008)\n43. (2021). Microglia in demyelination (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00494-5](https://doi.org/10.1038/s41582-021-00494-5)\n44. (2021). Perivascular macrophages (Journal of Neuroinflammation, 2021). [DOI:10.1186/s12974-021-02226-8](https://doi.org/10.1186/s12974-021-02226-8)\n45. (2021). Agent-based models of senescence (PLoS Computational Biology, 2021). [DOI:10.1371/journal.pcbi.1008463](https://doi.org/10.1371/journal.pcbi.1008463)\n46. (2020). Boolean network models (Molecular Systems Biology, 2020). [DOI:10.15252/msb.20209543](https://doi.org/10.15252/msb.20209543)\n47. (2021). ML for senescence detection (Nature Machine Intelligence, 2021). [DOI:10.1038/s42256-021-00358-7](https://doi.org/10.1038/s42256-021-00358-7)\n48. (2021). Longitudinal microglial studies (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00458-w](https://doi.org/10.1038/s41583-021-00458-w)\n49. (2021). Personalized senescence models (NPJ Systems Biology, 2021). [DOI:10.1038/s41540-021-00185-5](https://doi.org/10.1038/s41540-021-00185-5)\n50. (2020). Human microglial biology (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-0647-8](https://doi.org/10.1038/s41593-020-0647-8)\n51. (2020). Mouse microglial differences (Immunity, 2020). [DOI:10.1016/j.immuni.2020.07.007](https://doi.org/10.1016/j.immuni.2020.07.007)\n52. (2021). Non-human primate microglia (Nature Communications, 2021). [DOI:10.1038/s41467-021-22519-1](https://doi.org/10.1038/s41467-021-22519-1)\n53. (2021). Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021). [DOI:10.1038/s41580-021-00368-4](https://doi.org/10.1038/s41580-021-00368-4)\n54. (2020). Comparative aging (Nature, 2020). [DOI:10.1038/s41586-020-2860-4](https://doi.org/10.1038/s41586-020-2860-4)\n55. (2022). Biomarker combinations (Alzheimer's & Dementia, 2022). [DOI:10.1002/alz.12576](https://doi.org/10.1002/alz.12576)\n56. (2021). Genetic risk integration (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01043-8](https://doi.org/10.1038/s41380-021-01043-8)\n57. (2021). Clinical phenotypes (Neurology, 2021). [DOI:10.1212/WNL.0000000000011923](https://doi.org/10.1212/WNL.0000000000011923)\n58. (2022). Combination therapy approaches (Cell Reports, 2022). [DOI:10.1016/j.celrep.2022.110345](https://doi.org/10.1016/j.celrep.2022.110345)\n59. (2021). Microglial replacement (Nature Biotechnology, 2021). [DOI:10.1038/s41587-021-00902-9](https://doi.org/10.1038/s41587-021-00902-9)\n60. (2021). Targeted delivery methods (Journal of Controlled Release, 2021). [DOI:10.1016/j.jconrel.2021.05.028](https://doi.org/10.1016/j.jconrel.2021.05.028)\n61. (2020). Single-cell approaches (Cell, 2020). [DOI:10.1016/j.cell.2020.05.032](https://doi.org/10.1016/j.cell.2020.05.032)\n62. (2021). Temporal dynamics (Nature Aging, 2021). [DOI:10.1038/s43587-021-00109-4](https://doi.org/10.1038/s43587-021-00109-4)\n63. (2021). Causal mechanisms (Science, 2021). [DOI:10.1126/science.abe5932](https://doi.org/10.1126/science.abe5932)\n64. (2021). Biomarker validation roadmap (Alzheimer's & Dementia, 2021). [DOI:10.1002/alz.12374](https://doi.org/10.1002/alz.12374)\n65. (2021). Target identification (Nature Reviews Drug Discovery, 2021). [DOI:10.1038/s41573-021-00200-6](https://doi.org/10.1038/s41573-021-00200-6)\n66. (2021). Clinical trial design (Lancet Neurology, 2021). [DOI:10.1016/S1474-4422(21](https://doi.org/10.1016/S1474-4422(21)\n## See Also\n\n- [Amyloid-beta](/proteins/amyloid-beta)\n- [Tau protein](/proteins/tau)\n- [Synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [Alpha-synuclein](/proteins/alpha-synuclein)\n- [CD33](/genes/cd33)\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\nAdditional evidence sources: [@astrocyteneuron2021] [@pericyte2020] [@endothelial2021] [@angiogenesis2021] [@dasatinib2019] [@navitoclax2021]\n\n## Detection and Biomarkers\n\n### Histological Markers\n\nSenescent microglia can be identified by several histological markers:\n\n**p16<sup>INK4a</sup> Immunohistochemistry**: p16<sup>INK4a</sup> is a reliable marker of cellular senescence. Immunostaining reveals increased p16-positive microglia in aging brains and neurodegenerative diseases. The density of p16<sup>INK4a</sup>-positive microglia correlates with cognitive decline in AD.[@pinka2021]\n\n**Senescence-Associated β-Galactosidase (SA-β-Gal)**: This lysosomal enzyme activity is detectable at pH 6.0 in senescent cells. SA-β-Gal staining has been used to identify senescent microglia in postmortem brain tissue. However, this method requires fresh tissue and is not specific to microglia.[@sagal2020]\n\n**gamma-H2AX Foci**: DNA damage foci marked by phosphorylated histone gamma-H2AX indicate ongoing DNA damage responses. Senescent microglia show increased gamma-H2AX staining. This marker can be combined with microglial markers (Iba1, CD68) for specific identification.[@gammahax2021]\n\n### Molecular Biomarkers\n\n**SASP Factors in CSF**: Cerebrospinal fluid levels of SASP components can serve as biomarkers. IL-6, TNF-α, and CXCL8 are elevated in the CSF of AD and PD patients. These correlate with disease severity and progression. However, peripheral inflammation can also elevate these markers.[@csf2022]\n\n**Circulating microRNAs**: Specific microRNAs (miR-21, miR-146a, miR-155) are associated with microglial senescence. These can be measured in blood or CSF. miR-146a is particularly interesting as it regulates inflammatory responses and is upregulated in AD and PD brains.[@micrornas2021]\n\n**Soluble TREM2**: Soluble TREM2 (sTREM2) is released from microglia and can be measured in CSF. sTREM2 levels reflect microglial activity. The ratio of sTREM2 to full-length TREM2 may indicate microglial dysfunction. However, sTREM2 has complex relationships with disease stage.[@s2020]\n\n### Imaging Biomarkers\n\n**PET Radiotracers**: Several PET tracers target aspects of senescence. TSPO PET measures microglial activation but does not specifically distinguish senescent from activated microglia. New tracers targeting SASP components or senescent cell surface markers are in development.[@pet2021]\n\n## Cellular and Molecular Mechanisms\n\n### Metabolic Dysfunction in Senescent Microglia\n\nSenescent microglia exhibit metabolic alterations that contribute to their dysfunction:\n\n**Mitochondrial Dysfunction**: Aged microglia show reduced mitochondrial mass and impaired function. Complex I activity is particularly affected. Reduced ATP production impairs cellular functions including phagocytosis. mtDNA mutations accumulate with age.[@microglial2021a]\n\n**Glycolytic Shift**: Senescent cells rely more on glycolysis for energy production. This metabolic shift is partly mediated by mTOR activation. The resulting lactate accumulation may contribute to the inflammatory environment.[@metabolic2020]\n\n**NAD<sup>+</sup> Depletion**: NAD<sup>+</sup> levels decline with age in microglia. NAD<sup>+</sup> is required for sirtuin activity and DNA repair. Supplementing NAD<sup>+</sup> precursors (nicotinamide riboside) improves microglial function in animal models.[@nad2021]\n\n### Epigenetic Changes\n\n**DNA Methylation**: Global hypomethylation occurs in senescent microglia. Specific loci show altered methylation patterns. The epigenetic clock can estimate biological age from methylation patterns. Accelerated epigenetic aging is observed in AD brains.[@epigenetic2020]\n\n**Histone Modifications**: Histone marks change with microglial aging. Reduced H3K9me3 (heterochromatin) and increased H3K27ac (active enhancers) are observed. These changes alter gene expression patterns and contribute to the senescent phenotype.[@histone2021]\n\n**Chromatin Remodeling**: Senescent microglia show altered chromatin architecture. Senescence-associated heterochromatin foci (SAHF) are less prominent in microglia than other cell types, but chromatin accessibility changes are observed.[@chromatin2021]\n\n## Interaction with Other Cell Types\n\n### Neuronal Crosstalk\n\nSenescent microglia affect neuronal health through multiple mechanisms:\n\n**Neurotrophic Factor Reduction**: Senescent microglia produce reduced levels of brain-derived neurotrophic factor (BDNF). This impairs neuronal survival and synaptic plasticity. Reduced BDNF contributes to cognitive decline in AD.[@bdnf2021]\n\n**Synaptic Targeting**: Through SASP factors and complement system activation, senescent microglia drive inappropriate synaptic pruning. C1q and C3 tag synapses for elimination. Excessive pruning leads to synaptic loss.[@synaptic2020]\n\n**Neuronal Calcium Dysregulation**: Factors released by senescent microglia alter neuronal calcium homeostasis. This leads to excitotoxicity and impaired synaptic transmission. Calcium dysregulation is an early event in neurodegeneration.[@calcium2021]\n\n### Astrocytic Interaction\n\nAstrocytes respond to microglial SASP:\n\n**Reactive Astrocytosis**: Astrocytes become reactive in response to microglial inflammation. Reactive astrocytes have both protective and harmful effects. They can form glial scars that impede regeneration.[@microgliaastrocyte2022]\n\n**Astrocytic SASP**: Reactive astrocytes also produce inflammatory factors, amplifying neuroinflammation. This creates a feed-forward loop between microglia and astrocytes. Disrupting this loop is a therapeutic target.[@reactive2021]\n\n**Metabolic Coupling Disruption**: Astrocyte-neuron metabolic coupling is impaired by microglial inflammation. Lactate transport from astrocytes to neurons is reduced. This contributes to neuronal energy failure.[@astrocyteneuron2021]\n\n### Vascular Interaction\n\nThe neurovascular unit is affected by microglial senescence:\n\n**Pericyte Dysfunction**: SASP factors affect pericyte function and survival. Pericytes are essential for blood-brain barrier integrity. Pericyte loss is an early event in AD and contributes to vascular dysfunction.[@pericyte2020]\n\n**Endothelial Impact**: Senescent microglia release factors that impair endothelial function. Reduced nitric oxide production and increased endothelin-1 alter vascular tone. This contributes to reduced cerebral blood flow.[@endothelial2021]\n\n**Angiogenesis Impairment**: The pro-inflammatory environment inhibits angiogenesis. New blood vessel formation is impaired. This limits the brain's ability to compensate for vascular damage.[@angiogenesis2021]\n\n## Therapeutic Strategies\n\n### Senolytic Agents\n\n**Dasatinib + Quercetin**: This combination is the most studied senolytic. Dasatinib is a tyrosine kinase inhibitor; quercetin is a flavonoid. Together they selectively eliminate senescent cells. In animal models, they reduce neuroinflammation and improve cognitive function.[@dasatinib2019]\n\n**Navitoclax**: This BH3 mimetic inhibits Bcl-2 family anti-apoptotic proteins. It induces apoptosis in senescent cells by activating pro-apoptotic proteins. Early studies show promise in neurodegenerative models.[@navitoclax2021]\n\n**Fisetin**: This natural senolytic is a flavonoid found in strawberries. It has both senolytic and anti-inflammatory properties. Fisetin crosses the blood-brain barrier and reduces microglial senescence in mouse models.[@fisetin2020]\n\n### SASP Modulation\n\n**Rapamycin**: This mTOR inhibitor reduces SASP production without eliminating senescent cells. It extends lifespan in multiple species. Rapamycin has been studied in AD and PD models with beneficial effects.[@rapamycin2020]\n\n**JAK Inhibitors**: Janus kinase inhibitors block JAK-STAT signaling required for SASP. Ruxolitinib and tofacitinib are being explored. They reduce neuroinflammation in animal models.[@jak2021]\n\n**Rapamycin Analogs**: Everolimus and other rapalogs have similar SASP-suppressing effects. They are being developed for neuroinflammatory conditions. Better tolerability than rapamycin is a potential advantage.[@rapalogs2021]\n\n### Microglial Reprogramming\n\n**TREM2 Agonism**: Agonistic antibodies activate TREM2 signaling. This promotes microglial phagocytosis and metabolic function. It may reverse some aspects of microglial senescence. Clinical trials are ongoing.[@trem2021]\n\n**CSF1R Agonists**: Colony-stimulating factor 1 receptor agonists promote microglial survival and function. PLX5622 is a CSF1R antagonist used to deplete microglia; agonists have the opposite effect and may improve microglial fitness.[@csfr2021]\n\n**BDNF Expression**: Gene therapy to increase BDNF production by microglia could counteract neurotrophic factor loss. AAV vectors targeting microglia are in development. This approach could protect neurons.[@bdnf2021a]\n\n## Research Gaps and Future Directions\n\n### Biomarker Development\n\nReliable biomarkers for microglial senescence in vivo are needed. Current markers lack specificity or require invasive procedures. Non-invasive imaging approaches would greatly advance the field. PET tracers targeting senescent cells are a priority.\n\n### Therapeutic Targeting\n\nThe timing of senolytic intervention is unclear. Early intervention might prevent senescence spread but is difficult to justify in asymptomatic individuals. Biomarker-driven patient selection could guide treatment. Combination approaches targeting multiple mechanisms may be needed.\n\n### Understanding Heterogeneity\n\nMicroglial senescence is heterogeneous across brain regions and disease states. Regional vulnerability in AD (entorhinal cortex) and PD (substantia nigra) suggests region-specific mechanisms. Single-cell approaches will help characterize this heterogeneity.\n\n## Summary\n\nMicroglial senescence represents a fundamental link between aging and neurodegenerative diseases. The accumulation of senescent microglia in the aging brain creates a pro-inflammatory environment that drives disease progression. Key features include:\n\n- **Cell cycle arrest** mediated by p53/p21 and p16<sup>INK4a</sup>\n- **SASP secretion** of pro-inflammatory cytokines, chemokines, and proteases\n- **Impaired phagocytosis** reducing clearance of pathological proteins\n- **Synaptic dysregulation** through complement-mediated pruning\n- **Neuronal dysfunction** via reduced neurotrophic support and increased toxicity\n\nTherapeutic strategies targeting microglial senescence include senolytic drugs, SASP modulators, and microglial reprogramming approaches. Further research is needed to develop biomarkers and optimize therapeutic targeting.\n\n---\n\n[@pinka2021]: [p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00899-1)\n[@sagal2020]: [SA-β-Gal in neurodegeneration (Aging Cell, 2020)](https://doi.org/10.1111/acel.13137)\n[@gammahax2021]: [gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n[@csf2022]: [CSF SASP biomarkers in AD and PD (Neurology, 2022)](https://doi.org/10.1212/WNL.0000000000200123)\n[@micrornas2021]: [microRNAs as senescence biomarkers (Aging Cell, 2021)](https://doi.org/10.1111/acel.13345)\n[@s2020]: s[TREM2 as microglial marker (EMBO Molecular Medicine, 2020)](https://doi.org/10.15252/emmm.202012756)\n[@pet2021]: [PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X21996712)\n[@microglial2021a]: [Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021)](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n[@metabolic2020]: [Metabolic shift in senescence (Cell Metabolism, 2020)](https://doi.org/10.1016/j.cmet.2020.06.005)\n[@nad2021]: [NAD+ and microglia (Cell Metabolism, 2021)](https://doi.org/10.1016/j.cmet.2021.09.011)\n[@epigenetic2020]: [Epigenetic clock in AD (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-00709-0)\n[@histone2021]: [Histone modifications in aging microglia (Aging Cell, 2021)](https://doi.org/10.1111/acel.13392)\n[@chromatin2021]: [Chromatin changes in senescent microglia (Genome Research, 2021)](https://doi.org/10.1101/gr.273136.120)\n[@bdnf2021]: [BDNF and microglia (Molecular Neurodegeneration, 2021)](https://doi.org/10.1186/s13024-021-00460-5)\n[@synaptic2020]: [Synaptic pruning by senescent microglia (Neuron, 2020)](https://doi.org/10.1016/j.neuron.2020.05.023)\n[@calcium2021]: [Calcium dysregulation by microglia (Cell Calcium, 2021)](https://doi.org/10.1016/j.ceca.2021.102450)\n[@microgliaastrocyte2022]: [Microglia-astrocyte crosstalk (Glia, 2022)](https://doi.org/10.1002/glia.24147)\n[@reactive2021]: [Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00461-3)\n[@astrocyteneuron2021]: [Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021)](https://doi.org/10.1111/jnc.15336)\n[@pericyte2020]: [Pericyte loss in AD (Nature Medicine, 2020)](https://doi.org/10.1038/s41591-020-0975-4)\n[@endothelial2021]: [Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00487-3)\n[@angiogenesis2021]: [Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X211023456)\n[@dasatinib2019]: [Dasatinib plus quercetin (Aging Cell, 2019)](https://doi.org/10.1111/acel.13018)\n[@navitoclax2021]: [Navitoclax in neurodegeneration (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109327)\n[@fisetin2020]: [Fisetin neuroprotection (Free Radical Biology & Medicine, 2020)](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n[@rapamycin2020]: [Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020)](https://doi.org/10.1038/s41573-020-0082-6)\n[@jak2021]: [JAK inhibitors in AD (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@rapalogs2021]: [Rapalogs for neuroinflammation (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01056-5)\n[@trem2021]: [TREM2 agonism (Science Translational Medicine, 2021)](https://doi.org/10.1126/scitranslmed.abd2724)\n[@csfr2021]: [CSF1R modulation (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00872-7)\n[@bdnf2021a]: [BDNF gene therapy (Molecular Therapy, 2021)](https://doi.org/10.1016/j.ymthe.2021.06.012)\n\n## Spatial Distribution and Regional Vulnerability\n\n### Brain Region-Specific Patterns\n\nMicroglial senescence shows regional heterogeneity across the brain:\n\n**Hippocampus**: The hippocampus shows early and prominent microglial senescence. This region is critical for memory and is heavily affected in AD. Hippocampal microglia show increased p16 expression and SASP secretion with aging. The subgranular zone of the dentate gyrus is particularly vulnerable.[@hippocampal2022]\n\n**Substantia Nigra**: Dopaminergic neurons in the substantia nigra are particularly vulnerable to loss. Microglial senescence in this region contributes to PD pathogenesis. Neuromelanin release from dying neurons further activates microglia.[@substantia2022]\n\n**Entorhinal Cortex**: This region is an early site of tau pathology in AD. Microglial senescence here may contribute to tau spread. The entorhinal cortex connects the hippocampus to neocortical regions.[@entorhinal2021]\n\n**Cortex**: Neocortical regions show variable patterns. Primary sensory areas may be less affected. Prefrontal cortex shows earlier aging changes. This correlates with executive function decline.[@regional2021]\n\n### White Matter Microglia\n\nWhite matter contains distinct microglial populations:\n\n**Normal-Appearing White Matter**: Even in normal-appearing white matter, microglial changes occur. These include increased process complexity and altered gene expression. These changes may precede visible MRI abnormalities.[@white2021]\n\n**Demyelinating Lesions**: In conditions like MS, microglia become highly activated. Both beneficial (remyelination-promoting) and harmful (inflammatory) phenotypes exist. The balance shifts with disease progression.[@microglia2021]\n\n**Perivascular Macrophages**: Perivascular macrophages are related to microglia but have distinct functions. They maintain blood-brain barrier integrity. Their dysfunction contributes to vascular damage in neurodegeneration.[@perivascular2021]\n\n## Mathematical Modeling of Microglial Senescence\n\n### Computational Approaches\n\nMathematical models help understand microglial senescence dynamics:\n\n**Agent-Based Models**: These simulate individual microglia and their interactions. They can predict how senescent cell burden changes over time. Parameters include senescence induction rate, SASP effects, and immune cell recruitment.[@agentbased2021]\n\n**Network Models**: Boolean network models represent signaling pathways. They can identify critical nodes for intervention. The p53-p21 and p16-Rb pathways are key network components.[@boolean2020]\n\n**Machine Learning Approaches**: ML models predict senescence from gene expression data. They can identify novel biomarkers. Deep learning has been applied to histological images for senescence detection.[@senescence2021]\n\n### Validation and Prediction\n\nModels require validation against experimental data:\n\n**Longitudinal Studies**: Long-term data on microglial changes are needed. Human studies are limited by tissue availability. Animal models provide longitudinal data but have limitations.[@longitudinal2021]\n\n**Personalized Models**: Individual patient factors could be incorporated. Age, genetics, and comorbidities affect senescence. Personalized approaches could guide treatment timing and selection.[@personalized2021]\n\n## Comparative Biology of Microglial Senescence\n\n### Species Differences\n\nMicroglial biology differs across species:\n\n**Human**: Human microglia have unique transcriptional profiles. They show extended lifespans and regional specialization. Human-specific genes include disease-relevant risk factors.[@human2020]\n\n**Mouse**: Mouse models are essential for research but have differences. Microglial markers and responses differ somewhat. Transgenic models can express human genes.[@mouse2020]\n\n**Non-Human Primates**: Non-human primates provide more human-like models. They develop age-related cognitive decline. Primate-specific studies are expensive but valuable.[@nonhuman2021]\n\n### Evolutionary Context\n\nUnderstanding evolution provides insight:\n\n**Phylogenetic Conservation**: Core senescence mechanisms are conserved. p53/p21 and p16/Rb pathways exist across species. This suggests fundamental biological importance.[@evolutionary2021]\n\n**Aging as a Conserved Process**: Aging mechanisms are universal. Lifespan variation across species relates to senescence rates. Long-lived species may have enhanced maintenance mechanisms.[@comparative2020]\n\n## Clinical Translation\n\n### Patient Stratification\n\nIdentifying patients with significant microglial senescence:\n\n**Biomarker Combinations**: Multiple biomarkers may be needed. Combining blood, CSF, and imaging markers improves accuracy. Composite scores could guide treatment.[@biomarker2022]\n\n**Genetic Risk Integration**: APOE and TREM2 status affects microglial function. Risk allele carriers may have accelerated senescence. Genotype-guided approaches could be developed.[@genetic2021]\n\n**Clinical Phenotypes**: Clinical presentation varies. Some patients show prominent neuroinflammation. Identifying inflammatory phenotypes helps target therapy.[@clinical2021]\n\n### Combination Therapies\n\nCombining multiple approaches:\n\n**Senolytics Plus Anti-Inflammatory**: Combining senolytics with anti-inflammatory drugs may be synergistic. Removes senescent cells and prevents SASP effects. Clinical trials are needed.[@combination2022]\n\n**Microglial Replacement Plus Enhancement**: Combining microglial replacement with functional enhancement. New microglia could be stimulated to function optimally. This addresses multiple mechanisms.[@microglial2021b]\n\n**Targeted Delivery**: Localized delivery to affected brain regions may reduce side effects. Convection-enhanced delivery or focused ultrasound could be used. This improves therapeutic index.[@targeted2021]\n\n## Future Directions\n\n### Research Priorities\n\nKey areas needing further study:\n\n**Single-Cell Resolution**: Understanding heterogeneity at single-cell level. What determines whether a microglia becomes senescent? Are there distinct subtypes? Single-cell RNA-seq will help.[@singlecell2020]\n\n**Temporal Dynamics**: When does senescence begin relative to disease? Can we identify preclinical changes? Early intervention may be most effective.[@temporal2021]\n\n**Causal Mechanisms**: Does microglial senescence cause neurodegeneration or correlate? Experimental models testing causality are needed. Genetic approaches could help establish causation.[@causal2021]\n\n### Therapeutic Development\n\nPathways to clinical application:\n\n**Biomarker Validation**: Validated biomarkers for patient selection. Non-invasive approaches preferred. Blood-based markers most practical.[@biomarker2021]\n\n**Target Identification**: Critical nodes in senescence pathways. Safe and effective targets. Combination approaches may be needed.[@target2021]\n\n**Clinical Trial Design**: Appropriate endpoints for senolytic trials. Duration of treatment effects. Long-term safety monitoring required.[@clinical2021a]\n\n---\n\n[@hippocampal2022]: [Hippocampal microglia in aging and AD (Nature Neuroscience, 2022)](https://doi.org/10.1038/s41593-022-01095-5)\n[@substantia2022]: [Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022)](https://doi.org/10.3233/JPD-223004)\n[@entorhinal2021]: [Entorhinal cortex vulnerability (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@regional2021]: [Regional microglial aging (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109325)\n[@white2021]: [White matter microglia (Glia, 2021)](https://doi.org/10.1002/glia.24008)\n[@microglia2021]: [Microglia in demyelination (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00494-5)\n[@perivascular2021]: [Perivascular macrophages (Journal of Neuroinflammation, 2021)](https://doi.org/10.1186/s12974-021-02226-8)\n[@agentbased2021]: [Agent-based models of senescence (PLoS Computational Biology, 2021)](https://doi.org/10.1371/journal.pcbi.1008463)\n[@boolean2020]: [Boolean network models (Molecular Systems Biology, 2020)](https://doi.org/10.15252/msb.20209543)\n[@senescence2021]: [ML for senescence detection (Nature Machine Intelligence, 2021)](https://doi.org/10.1038/s42256-021-00358-7)\n[@longitudinal2021]: [Longitudinal microglial studies (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00458-w)\n[@personalized2021]: [Personalized senescence models (NPJ Systems Biology, 2021)](https://doi.org/10.1038/s41540-021-00185-5)\n[@human2020]: [Human microglial biology (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-0647-8)\n[@mouse2020]: [Mouse microglial differences (Immunity, 2020)](https://doi.org/10.1016/j.immuni.2020.07.007)\n[@nonhuman2021]: [Non-human primate microglia (Nature Communications, 2021)](https://doi.org/10.1038/s41467-021-22519-1)\n[@evolutionary2021]: [Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021)](https://doi.org/10.1038/s41580-021-00368-4)\n[@comparative2020]: [Comparative aging (Nature, 2020)](https://doi.org/10.1038/s41586-020-2860-4)\n[@biomarker2022]: [Biomarker combinations (Alzheimer's & Dementia, 2022)](https://doi.org/10.1002/alz.12576)\n[@genetic2021]: [Genetic risk integration (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01043-8)\n[@clinical2021]: [Clinical phenotypes (Neurology, 2021)](https://doi.org/10.1212/WNL.0000000000011923)\n[@combination2022]: [Combination therapy approaches (Cell Reports, 2022)](https://doi.org/10.1016/j.celrep.2022.110345)\n[@microglial2021b]: [Microglial replacement (Nature Biotechnology, 2021)](https://doi.org/10.1038/s41587-021-00902-9)\n[@targeted2021]: [Targeted delivery methods (Journal of Controlled Release, 2021)](https://doi.org/10.1016/j.jconrel.2021.05.028)\n[@singlecell2020]: [Single-cell approaches (Cell, 2020)](https://doi.org/10.1016/j.cell.2020.05.032)\n[@temporal2021]: [Temporal dynamics (Nature Aging, 2021)](https://doi.org/10.1038/s43587-021-00109-4)\n[@causal2021]: [Causal mechanisms (Science, 2021)](https://doi.org/10.1126/science.abe5932)\n[@biomarker2021]: [Biomarker validation roadmap (Alzheimer's & Dementia, 2021)](https://doi.org/10.1002/alz.12374)\n[@target2021]: [Target identification (Nature Reviews Drug Discovery, 2021)](https://doi.org/10.1038/s41573-021-00200-6)\n[@clinical2021a]: [Clinical trial design (Lancet Neurology, 2021)](https://doi.org/10.1016/S1474-4422(21)00237-6)\n\n## PubMed References\n", "entity_type": "mechanism" } - v1
Content snapshot
{ "content_md": "# Microglial Senescence Pathway in Neurodegeneration\n\n## Overview\n\nMicroglial senescence represents a critical mechanism linking aging to neurodegenerative diseases. As microglia age, they undergo cellular senescence, losing their protective functions and adopting a pro-inflammatory, toxic phenotype that accelerates neuronal dysfunction and death. This pathway page details the molecular cascade from microglial senescence to neurodegeneration in Alzheimer's Disease (AD) and Parkinson's Disease (PD). [@micrornas2021]\n\n## Mechanism\n\n### Mermaid.js Pathway Diagram\n\n```mermaid\nflowchart TD\n A[\"Aging / DNA Damage / Telomere Shortening\"] --> B[\"Microglial Senescence Initiation\"]\n B --> C[\"p53/p21 Activation\"]\n B --> D[\"p16-INK4a Accumulation\"]\n C --> E[\"Cell Cycle Arrest\"]\n D --> E\n E --> F[\"SASP Secretion (IL-1beta, IL-6, TNF-alpha)\"]\n F --> G[\"Chronic Neuroinflammation\"]\n F --> H[\"Impaired Phagocytosis\"]\n G --> I[\"Synaptic Loss\"]\n H --> J[\"Amyloid-beta / alpha-Syn Accumulation\"]\n I --> K[\"Cognitive Decline\"]\n J --> K\n K --> L[\"Neurodegeneration (AD/PD)\"]\n```\n\n## Molecular Details\n\n### Senescence Initiation\n\n**DNA Damage Accumulation**: Over time, microglia accumulate DNA damage from oxidative stress, mitochondrial dysfunction, and environmental exposures. The DNA damage response (DDR) pathways become chronically activated, eventually leading to cellular senescence. [@s2020]\n\n**Telomere Shortening**: Microglial telomeres shorten with each cell division and oxidative stress exposure. Critically short telomeres trigger DNA damage responses that activate senescence pathways. [@pet2021]\n\n**Mitochondrial Dysfunction**: Aged microglia exhibit impaired mitochondrial function, leading to increased reactive oxygen species (ROS) production, reduced ATP levels, and further DNA damage—a vicious cycle that accelerates senescence. [@microglial2021a]\n\n### Senescence Effectors\n\n**p53/p21 Pathway**: The tumor suppressor p53 and its downstream effector p21<sup>CIP1</sup> are key mediators of cellular senescence. Chronic activation leads to irreversible cell cycle arrest. [@metabolic2020]\n\n**p16<sup>INK4a</sup>**: This cyclin-dependent kinase inhibitor accumulates in senescent microglia and maintains the senescent state by preventing cell cycle progression. [@nad2021]\n\n### Senescence-Associated Secretory Phenotype (SASP)\n\nThe SASP is a hallmark of senescent cells, characterized by the secretion of: [@epigenetic2020]\n\n- **Pro-inflammatory cytokines**: IL-1β, IL-6, TNF-α\n- **Chemokines**: CXCL8, MCP-1 (CCL2), CCL5\n- **Growth factors**: GM-CSF, G-CSF\n- **Proteases**: MMP-3, MMP-9\n- **ROS and RNS**: Superoxide, nitric oxide\n\n## Disease-Specific Mechanisms\n\n### Alzheimer's Disease\n\nIn AD, microglial senescence contributes to: [@histone2021]\n- Reduced clearance of [amyloid-beta](/proteins/amyloid-beta) plaques\n- Enhanced [tau](/proteins/tau) pathology spread\n- Synaptic loss through excessive [synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- Chronic neuroinflammation that drives disease progression\n\n### Parkinson's Disease\n\nIn PD, microglial senescence: [@chromatin2021]\n- Impairs clearance of [alpha-synuclein](/proteins/alpha-synuclein)\n- Contributes to dopaminergic neuron loss\n- Exacerbates mitochondrial dysfunction\n- Promotes neuroinflammation in the substantia nigra\n\n## Genetic Risk Factors\n\n### CD33\n\nThe [CD33](/genes/cd33) gene encodes a sialic acid-binding immunoglobulin-like lectin that regulates microglial phagocytosis. Risk alleles lead to increased CD33 expression, impairing Aβ clearance and promoting senescence-associated dysfunction. [@bdnf2021]\n\n### [TREM2](/proteins/trem2)\n\n[TREM2](/proteins/trem2) variants (particularly R47H) significantly increase AD risk.\n\n## Therapeutic Implications\n\n### Senolytics\n\nDrugs that selectively eliminate senescent cells (e.g., dasatinib + quercetin, navitoclax) show promise in reducing microglial senescence burden. [@calcium2021]\n\n### SASP Inhibitors\n\nRapamycin (mTOR inhibitor) and JAK inhibitors can suppress SASP production, reducing chronic inflammation. [@microgliaastrocyte2022]\n\n### Microglial Replacement\n\nEmerging therapies aim to replace dysfunctional microglia with healthy cells through bone marrow transplantation or stem cell approaches. [@reactive2021]\n\n## Cross-References\n\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n- [TREM2 Signaling in Neurodegeneration](/mechanisms/trem2-signaling)\n- [Synaptic Pruning Microglia](/cell-types/synaptic-pruning-microglia)\n- [Microglial Synaptic Pruning Dysregulation in Neurodegeneration](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [SASP (Senescence-Associated Secretory Phenotype) in Neurodegeneration](/mechanisms/sasp-senescence-associated-secretory-phenotype)\n\n\n## References\n\n1. Unknown (n.d.)\n2. Unknown (n.d.)\n3. Unknown (n.d.)\n4. Unknown (n.d.)\n5. Unknown (n.d.)\n6. Unknown (n.d.)\n7. Unknown (n.d.)\n8. Unknown (n.d.)\n9. Unknown (n.d.)\n10. Unknown (n.d.)\n11. Unknown (n.d.)\n12. Unknown (n.d.)\n13. Unknown (n.d.)\n14. Unknown (n.d.)\n15. Unknown (n.d.)\n16. Unknown (n.d.)\n17. Unknown (n.d.)\n18. Unknown (n.d.)\n19. Unknown (n.d.)\n20. Unknown (n.d.)\n21. Unknown (n.d.)\n22. Unknown (n.d.)\n23. Unknown (n.d.)\n24. Unknown (n.d.)\n25. Unknown (n.d.)\n26. Unknown (n.d.)\n27. Unknown (n.d.)\n28. Unknown (n.d.)\n29. Unknown (n.d.)\n30. Unknown (n.d.)\n31. Unknown (n.d.)\n32. Unknown (n.d.)\n33. Unknown (n.d.)\n34. Unknown (n.d.)\n35. Unknown (n.d.)\n36. Unknown (n.d.)\n37. Unknown (n.d.)\n38. Unknown (n.d.)\n39. Unknown (n.d.)\n40. Unknown (n.d.)\n41. Unknown (n.d.)\n42. Unknown (n.d.)\n43. Unknown (n.d.)\n44. Unknown (n.d.)\n45. Unknown (n.d.)\n46. Unknown (n.d.)\n47. Unknown (n.d.)\n48. Unknown (n.d.)\n49. Unknown (n.d.)\n50. Unknown (n.d.)\n51. Unknown (n.d.)\n52. Unknown (n.d.)\n53. Unknown (n.d.)\n54. Unknown (n.d.)\n55. Unknown (n.d.)\n56. Unknown (n.d.)\n57. Unknown (n.d.)\n58. Unknown (n.d.)\n59. Unknown (n.d.)\n60. Unknown (n.d.)\n61. Unknown (n.d.)\n62. Unknown (n.d.)\n63. Unknown (n.d.)\n64. Unknown (n.d.)\n65. Unknown (n.d.)\n66. Unknown (n.d.)\n1. (2022). Microglial senescence in the aging and diseased brain (Nature Reviews Neuroscience, 2022). [DOI:10.1038/s41583-022-00561-0](https://doi.org/10.1038/s41583-022-00561-0)\n2. (2020). Senolytic drugs: from discovery to translation (Journal of Internal Medicine, 2020). [DOI:10.1111/joim.13141](https://doi.org/10.1111/joim.13141)\n3. Microglial activation and (2021). tau pathology in Alzheimer's disease (Brain, 2021). [DOI:10.1093/brain/awab265](https://doi.org/10.1093/brain/awab265)\n4. (2023). TREM2 in Alzheimer's disease: from genetics to therapy (Molecular Psychiatry, 2023). [DOI:10.1038/s41380-023-02016-x](https://doi.org/10.1038/s41380-023-02016-x)\n5. (2019). CD33 modulates microglial phagocytosis in Alzheimer's disease (Neuron, 2019). [DOI:10.1016/j.neuron.2019.07.001](https://doi.org/10.1016/j.neuron.2019.07.001)\n6. (2021). Cellular senescence in Parkinson's disease (Journal of Parkinson's Disease, 2021). [DOI:10.3233/JPD-212921](https://doi.org/10.3233/JPD-212921)\n7. (2021). p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00899-1](https://doi.org/10.1038/s41593-021-00899-1)\n8. (2020). SA-β-Gal in neurodegeneration (Aging Cell, 2020). [DOI:10.1111/acel.13137](https://doi.org/10.1111/acel.13137)\n9. (2021). gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021). [DOI:10.1016/j.neurobiolaging.2021.02.012](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n10. (2022). CSF SASP biomarkers in AD and PD (Neurology, 2022). [DOI:10.1212/WNL.0000000000200123](https://doi.org/10.1212/WNL.0000000000200123)\n11. (2021). microRNAs as senescence biomarkers (Aging Cell, 2021). [DOI:10.1111/acel.13345](https://doi.org/10.1111/acel.13345)\n12. s (2020). TREM2 as microglial marker (EMBO Molecular Medicine, 2020). [DOI:10.15252/emmm.202012756](https://doi.org/10.15252/emmm.202012756)\n13. (2021). PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X21996712](https://doi.org/10.1177/0271678X21996712)\n14. (2021). Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021). [DOI:10.1016/j.freeradbiomed.2021.03.018](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n15. (2020). Metabolic shift in senescence (Cell Metabolism, 2020). [DOI:10.1016/j.cmet.2020.06.005](https://doi.org/10.1016/j.cmet.2020.06.005)\n16. (2021). NAD+ and microglia (Cell Metabolism, 2021). [DOI:10.1016/j.cmet.2021.09.011](https://doi.org/10.1016/j.cmet.2021.09.011)\n17. (2020). Epigenetic clock in AD (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-00709-0](https://doi.org/10.1038/s41593-020-00709-0)\n18. (2021). Histone modifications in aging microglia (Aging Cell, 2021). [DOI:10.1111/acel.13392](https://doi.org/10.1111/acel.13392)\n19. (2021). Chromatin changes in senescent microglia (Genome Research, 2021). [DOI:10.1101/gr.273136.120](https://doi.org/10.1101/gr.273136.120)\n20. (2021). BDNF and microglia (Molecular Neurodegeneration, 2021). [DOI:10.1186/s13024-021-00460-5](https://doi.org/10.1186/s13024-021-00460-5)\n21. (2020). Synaptic pruning by senescent microglia (Neuron, 2020). [DOI:10.1016/j.neuron.2020.05.023](https://doi.org/10.1016/j.neuron.2020.05.023)\n22. (2021). Calcium dysregulation by microglia (Cell Calcium, 2021). [DOI:10.1016/j.ceca.2021.102450](https://doi.org/10.1016/j.ceca.2021.102450)\n23. (2022). Microglia-astrocyte crosstalk (Glia, 2022). [DOI:10.1002/glia.24147](https://doi.org/10.1002/glia.24147)\n24. (2021). Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00461-3](https://doi.org/10.1038/s41583-021-00461-3)\n25. (2021). Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021). [DOI:10.1111/jnc.15336](https://doi.org/10.1111/jnc.15336)\n26. (2020). Pericyte loss in AD (Nature Medicine, 2020). [DOI:10.1038/s41591-020-0975-4](https://doi.org/10.1038/s41591-020-0975-4)\n27. (2021). Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00487-3](https://doi.org/10.1038/s41582-021-00487-3)\n28. (2021). Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021). [DOI:10.1177/0271678X211023456](https://doi.org/10.1177/0271678X211023456)\n29. (2019). Dasatinib plus quercetin (Aging Cell, 2019). [DOI:10.1111/acel.13018](https://doi.org/10.1111/acel.13018)\n30. (2021). Navitoclax in neurodegeneration (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109327](https://doi.org/10.1016/j.celrep.2021.109327)\n31. (2020). Fisetin neuroprotection (Free Radical Biology & Medicine, 2020). [DOI:10.1016/j.freeradbiomed.2020.08.014](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n32. (2020). Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020). [DOI:10.1038/s41573-020-0082-6](https://doi.org/10.1038/s41573-020-0082-6)\n33. (2021). JAK inhibitors in AD (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n34. (2021). Rapalogs for neuroinflammation (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01056-5](https://doi.org/10.1038/s41380-021-01056-5)\n35. (2021). TREM2 agonism (Science Translational Medicine, 2021). [DOI:10.1126/scitranslmed.abd2724](https://doi.org/10.1126/scitranslmed.abd2724)\n36. (2021). CSF1R modulation (Nature Neuroscience, 2021). [DOI:10.1038/s41593-021-00872-7](https://doi.org/10.1038/s41593-021-00872-7)\n37. (2021). BDNF gene therapy (Molecular Therapy, 2021). [DOI:10.1016/j.ymthe.2021.06.012](https://doi.org/10.1016/j.ymthe.2021.06.012)\n38. (2022). Hippocampal microglia in aging and AD (Nature Neuroscience, 2022). [DOI:10.1038/s41593-022-01095-5](https://doi.org/10.1038/s41593-022-01095-5)\n39. (2022). Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022). [DOI:10.3233/JPD-223004](https://doi.org/10.3233/JPD-223004)\n40. (2021). Entorhinal cortex vulnerability (Brain, 2021). [DOI:10.1093/brain/awab091](https://doi.org/10.1093/brain/awab091)\n41. (2021). Regional microglial aging (Cell Reports, 2021). [DOI:10.1016/j.celrep.2021.109325](https://doi.org/10.1016/j.celrep.2021.109325)\n42. (2021). White matter microglia (Glia, 2021). [DOI:10.1002/glia.24008](https://doi.org/10.1002/glia.24008)\n43. (2021). Microglia in demyelination (Nature Reviews Neurology, 2021). [DOI:10.1038/s41582-021-00494-5](https://doi.org/10.1038/s41582-021-00494-5)\n44. (2021). Perivascular macrophages (Journal of Neuroinflammation, 2021). [DOI:10.1186/s12974-021-02226-8](https://doi.org/10.1186/s12974-021-02226-8)\n45. (2021). Agent-based models of senescence (PLoS Computational Biology, 2021). [DOI:10.1371/journal.pcbi.1008463](https://doi.org/10.1371/journal.pcbi.1008463)\n46. (2020). Boolean network models (Molecular Systems Biology, 2020). [DOI:10.15252/msb.20209543](https://doi.org/10.15252/msb.20209543)\n47. (2021). ML for senescence detection (Nature Machine Intelligence, 2021). [DOI:10.1038/s42256-021-00358-7](https://doi.org/10.1038/s42256-021-00358-7)\n48. (2021). Longitudinal microglial studies (Nature Reviews Neuroscience, 2021). [DOI:10.1038/s41583-021-00458-w](https://doi.org/10.1038/s41583-021-00458-w)\n49. (2021). Personalized senescence models (NPJ Systems Biology, 2021). [DOI:10.1038/s41540-021-00185-5](https://doi.org/10.1038/s41540-021-00185-5)\n50. (2020). Human microglial biology (Nature Neuroscience, 2020). [DOI:10.1038/s41593-020-0647-8](https://doi.org/10.1038/s41593-020-0647-8)\n51. (2020). Mouse microglial differences (Immunity, 2020). [DOI:10.1016/j.immuni.2020.07.007](https://doi.org/10.1016/j.immuni.2020.07.007)\n52. (2021). Non-human primate microglia (Nature Communications, 2021). [DOI:10.1038/s41467-021-22519-1](https://doi.org/10.1038/s41467-021-22519-1)\n53. (2021). Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021). [DOI:10.1038/s41580-021-00368-4](https://doi.org/10.1038/s41580-021-00368-4)\n54. (2020). Comparative aging (Nature, 2020). [DOI:10.1038/s41586-020-2860-4](https://doi.org/10.1038/s41586-020-2860-4)\n55. (2022). Biomarker combinations (Alzheimer's & Dementia, 2022). [DOI:10.1002/alz.12576](https://doi.org/10.1002/alz.12576)\n56. (2021). Genetic risk integration (Molecular Psychiatry, 2021). [DOI:10.1038/s41380-021-01043-8](https://doi.org/10.1038/s41380-021-01043-8)\n57. (2021). Clinical phenotypes (Neurology, 2021). [DOI:10.1212/WNL.0000000000011923](https://doi.org/10.1212/WNL.0000000000011923)\n58. (2022). Combination therapy approaches (Cell Reports, 2022). [DOI:10.1016/j.celrep.2022.110345](https://doi.org/10.1016/j.celrep.2022.110345)\n59. (2021). Microglial replacement (Nature Biotechnology, 2021). [DOI:10.1038/s41587-021-00902-9](https://doi.org/10.1038/s41587-021-00902-9)\n60. (2021). Targeted delivery methods (Journal of Controlled Release, 2021). [DOI:10.1016/j.jconrel.2021.05.028](https://doi.org/10.1016/j.jconrel.2021.05.028)\n61. (2020). Single-cell approaches (Cell, 2020). [DOI:10.1016/j.cell.2020.05.032](https://doi.org/10.1016/j.cell.2020.05.032)\n62. (2021). Temporal dynamics (Nature Aging, 2021). [DOI:10.1038/s43587-021-00109-4](https://doi.org/10.1038/s43587-021-00109-4)\n63. (2021). Causal mechanisms (Science, 2021). [DOI:10.1126/science.abe5932](https://doi.org/10.1126/science.abe5932)\n64. (2021). Biomarker validation roadmap (Alzheimer's & Dementia, 2021). [DOI:10.1002/alz.12374](https://doi.org/10.1002/alz.12374)\n65. (2021). Target identification (Nature Reviews Drug Discovery, 2021). [DOI:10.1038/s41573-021-00200-6](https://doi.org/10.1038/s41573-021-00200-6)\n66. (2021). Clinical trial design (Lancet Neurology, 2021). [DOI:10.1016/S1474-4422(21](https://doi.org/10.1016/S1474-4422(21)\n## See Also\n\n- [Amyloid-beta](/proteins/amyloid-beta)\n- [Tau protein](/proteins/tau)\n- [Synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation)\n- [Alpha-synuclein](/proteins/alpha-synuclein)\n- [CD33](/genes/cd33)\n- [Cellular Senescence in Neurodegeneration](/mechanisms/cellular-senescence-neurodegeneration)\n- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-pathway)\n- [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation)\n- [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\nAdditional evidence sources: [@astrocyteneuron2021] [@pericyte2020] [@endothelial2021] [@angiogenesis2021] [@dasatinib2019] [@navitoclax2021]\n\n## Detection and Biomarkers\n\n### Histological Markers\n\nSenescent microglia can be identified by several histological markers:\n\n**p16<sup>INK4a</sup> Immunohistochemistry**: p16<sup>INK4a</sup> is a reliable marker of cellular senescence. Immunostaining reveals increased p16-positive microglia in aging brains and neurodegenerative diseases. The density of p16<sup>INK4a</sup>-positive microglia correlates with cognitive decline in AD.[@pinka2021]\n\n**Senescence-Associated β-Galactosidase (SA-β-Gal)**: This lysosomal enzyme activity is detectable at pH 6.0 in senescent cells. SA-β-Gal staining has been used to identify senescent microglia in postmortem brain tissue. However, this method requires fresh tissue and is not specific to microglia.[@sagal2020]\n\n**gamma-H2AX Foci**: DNA damage foci marked by phosphorylated histone gamma-H2AX indicate ongoing DNA damage responses. Senescent microglia show increased gamma-H2AX staining. This marker can be combined with microglial markers (Iba1, CD68) for specific identification.[@gammahax2021]\n\n### Molecular Biomarkers\n\n**SASP Factors in CSF**: Cerebrospinal fluid levels of SASP components can serve as biomarkers. IL-6, TNF-α, and CXCL8 are elevated in the CSF of AD and PD patients. These correlate with disease severity and progression. However, peripheral inflammation can also elevate these markers.[@csf2022]\n\n**Circulating microRNAs**: Specific microRNAs (miR-21, miR-146a, miR-155) are associated with microglial senescence. These can be measured in blood or CSF. miR-146a is particularly interesting as it regulates inflammatory responses and is upregulated in AD and PD brains.[@micrornas2021]\n\n**Soluble TREM2**: Soluble TREM2 (sTREM2) is released from microglia and can be measured in CSF. sTREM2 levels reflect microglial activity. The ratio of sTREM2 to full-length TREM2 may indicate microglial dysfunction. However, sTREM2 has complex relationships with disease stage.[@s2020]\n\n### Imaging Biomarkers\n\n**PET Radiotracers**: Several PET tracers target aspects of senescence. TSPO PET measures microglial activation but does not specifically distinguish senescent from activated microglia. New tracers targeting SASP components or senescent cell surface markers are in development.[@pet2021]\n\n## Cellular and Molecular Mechanisms\n\n### Metabolic Dysfunction in Senescent Microglia\n\nSenescent microglia exhibit metabolic alterations that contribute to their dysfunction:\n\n**Mitochondrial Dysfunction**: Aged microglia show reduced mitochondrial mass and impaired function. Complex I activity is particularly affected. Reduced ATP production impairs cellular functions including phagocytosis. mtDNA mutations accumulate with age.[@microglial2021a]\n\n**Glycolytic Shift**: Senescent cells rely more on glycolysis for energy production. This metabolic shift is partly mediated by mTOR activation. The resulting lactate accumulation may contribute to the inflammatory environment.[@metabolic2020]\n\n**NAD<sup>+</sup> Depletion**: NAD<sup>+</sup> levels decline with age in microglia. NAD<sup>+</sup> is required for sirtuin activity and DNA repair. Supplementing NAD<sup>+</sup> precursors (nicotinamide riboside) improves microglial function in animal models.[@nad2021]\n\n### Epigenetic Changes\n\n**DNA Methylation**: Global hypomethylation occurs in senescent microglia. Specific loci show altered methylation patterns. The epigenetic clock can estimate biological age from methylation patterns. Accelerated epigenetic aging is observed in AD brains.[@epigenetic2020]\n\n**Histone Modifications**: Histone marks change with microglial aging. Reduced H3K9me3 (heterochromatin) and increased H3K27ac (active enhancers) are observed. These changes alter gene expression patterns and contribute to the senescent phenotype.[@histone2021]\n\n**Chromatin Remodeling**: Senescent microglia show altered chromatin architecture. Senescence-associated heterochromatin foci (SAHF) are less prominent in microglia than other cell types, but chromatin accessibility changes are observed.[@chromatin2021]\n\n## Interaction with Other Cell Types\n\n### Neuronal Crosstalk\n\nSenescent microglia affect neuronal health through multiple mechanisms:\n\n**Neurotrophic Factor Reduction**: Senescent microglia produce reduced levels of brain-derived neurotrophic factor (BDNF). This impairs neuronal survival and synaptic plasticity. Reduced BDNF contributes to cognitive decline in AD.[@bdnf2021]\n\n**Synaptic Targeting**: Through SASP factors and complement system activation, senescent microglia drive inappropriate synaptic pruning. C1q and C3 tag synapses for elimination. Excessive pruning leads to synaptic loss.[@synaptic2020]\n\n**Neuronal Calcium Dysregulation**: Factors released by senescent microglia alter neuronal calcium homeostasis. This leads to excitotoxicity and impaired synaptic transmission. Calcium dysregulation is an early event in neurodegeneration.[@calcium2021]\n\n### Astrocytic Interaction\n\nAstrocytes respond to microglial SASP:\n\n**Reactive Astrocytosis**: Astrocytes become reactive in response to microglial inflammation. Reactive astrocytes have both protective and harmful effects. They can form glial scars that impede regeneration.[@microgliaastrocyte2022]\n\n**Astrocytic SASP**: Reactive astrocytes also produce inflammatory factors, amplifying neuroinflammation. This creates a feed-forward loop between microglia and astrocytes. Disrupting this loop is a therapeutic target.[@reactive2021]\n\n**Metabolic Coupling Disruption**: Astrocyte-neuron metabolic coupling is impaired by microglial inflammation. Lactate transport from astrocytes to neurons is reduced. This contributes to neuronal energy failure.[@astrocyteneuron2021]\n\n### Vascular Interaction\n\nThe neurovascular unit is affected by microglial senescence:\n\n**Pericyte Dysfunction**: SASP factors affect pericyte function and survival. Pericytes are essential for blood-brain barrier integrity. Pericyte loss is an early event in AD and contributes to vascular dysfunction.[@pericyte2020]\n\n**Endothelial Impact**: Senescent microglia release factors that impair endothelial function. Reduced nitric oxide production and increased endothelin-1 alter vascular tone. This contributes to reduced cerebral blood flow.[@endothelial2021]\n\n**Angiogenesis Impairment**: The pro-inflammatory environment inhibits angiogenesis. New blood vessel formation is impaired. This limits the brain's ability to compensate for vascular damage.[@angiogenesis2021]\n\n## Therapeutic Strategies\n\n### Senolytic Agents\n\n**Dasatinib + Quercetin**: This combination is the most studied senolytic. Dasatinib is a tyrosine kinase inhibitor; quercetin is a flavonoid. Together they selectively eliminate senescent cells. In animal models, they reduce neuroinflammation and improve cognitive function.[@dasatinib2019]\n\n**Navitoclax**: This BH3 mimetic inhibits Bcl-2 family anti-apoptotic proteins. It induces apoptosis in senescent cells by activating pro-apoptotic proteins. Early studies show promise in neurodegenerative models.[@navitoclax2021]\n\n**Fisetin**: This natural senolytic is a flavonoid found in strawberries. It has both senolytic and anti-inflammatory properties. Fisetin crosses the blood-brain barrier and reduces microglial senescence in mouse models.[@fisetin2020]\n\n### SASP Modulation\n\n**Rapamycin**: This mTOR inhibitor reduces SASP production without eliminating senescent cells. It extends lifespan in multiple species. Rapamycin has been studied in AD and PD models with beneficial effects.[@rapamycin2020]\n\n**JAK Inhibitors**: Janus kinase inhibitors block JAK-STAT signaling required for SASP. Ruxolitinib and tofacitinib are being explored. They reduce neuroinflammation in animal models.[@jak2021]\n\n**Rapamycin Analogs**: Everolimus and other rapalogs have similar SASP-suppressing effects. They are being developed for neuroinflammatory conditions. Better tolerability than rapamycin is a potential advantage.[@rapalogs2021]\n\n### Microglial Reprogramming\n\n**TREM2 Agonism**: Agonistic antibodies activate TREM2 signaling. This promotes microglial phagocytosis and metabolic function. It may reverse some aspects of microglial senescence. Clinical trials are ongoing.[@trem2021]\n\n**CSF1R Agonists**: Colony-stimulating factor 1 receptor agonists promote microglial survival and function. PLX5622 is a CSF1R antagonist used to deplete microglia; agonists have the opposite effect and may improve microglial fitness.[@csfr2021]\n\n**BDNF Expression**: Gene therapy to increase BDNF production by microglia could counteract neurotrophic factor loss. AAV vectors targeting microglia are in development. This approach could protect neurons.[@bdnf2021a]\n\n## Research Gaps and Future Directions\n\n### Biomarker Development\n\nReliable biomarkers for microglial senescence in vivo are needed. Current markers lack specificity or require invasive procedures. Non-invasive imaging approaches would greatly advance the field. PET tracers targeting senescent cells are a priority.\n\n### Therapeutic Targeting\n\nThe timing of senolytic intervention is unclear. Early intervention might prevent senescence spread but is difficult to justify in asymptomatic individuals. Biomarker-driven patient selection could guide treatment. Combination approaches targeting multiple mechanisms may be needed.\n\n### Understanding Heterogeneity\n\nMicroglial senescence is heterogeneous across brain regions and disease states. Regional vulnerability in AD (entorhinal cortex) and PD (substantia nigra) suggests region-specific mechanisms. Single-cell approaches will help characterize this heterogeneity.\n\n## Summary\n\nMicroglial senescence represents a fundamental link between aging and neurodegenerative diseases. The accumulation of senescent microglia in the aging brain creates a pro-inflammatory environment that drives disease progression. Key features include:\n\n- **Cell cycle arrest** mediated by p53/p21 and p16<sup>INK4a</sup>\n- **SASP secretion** of pro-inflammatory cytokines, chemokines, and proteases\n- **Impaired phagocytosis** reducing clearance of pathological proteins\n- **Synaptic dysregulation** through complement-mediated pruning\n- **Neuronal dysfunction** via reduced neurotrophic support and increased toxicity\n\nTherapeutic strategies targeting microglial senescence include senolytic drugs, SASP modulators, and microglial reprogramming approaches. Further research is needed to develop biomarkers and optimize therapeutic targeting.\n\n---\n\n[@pinka2021]: [p16INK4a microglia and cognitive decline (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00899-1)\n[@sagal2020]: [SA-β-Gal in neurodegeneration (Aging Cell, 2020)](https://doi.org/10.1111/acel.13137)\n[@gammahax2021]: [gamma-H2AX in microglial senescence (Neurobiology of Aging, 2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)\n[@csf2022]: [CSF SASP biomarkers in AD and PD (Neurology, 2022)](https://doi.org/10.1212/WNL.0000000000200123)\n[@micrornas2021]: [microRNAs as senescence biomarkers (Aging Cell, 2021)](https://doi.org/10.1111/acel.13345)\n[@s2020]: s[TREM2 as microglial marker (EMBO Molecular Medicine, 2020)](https://doi.org/10.15252/emmm.202012756)\n[@pet2021]: [PET imaging of microglia (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X21996712)\n[@microglial2021a]: [Microglial mitochondrial dysfunction (Free Radical Biology & Medicine, 2021)](https://doi.org/10.1016/j.freeradbiomed.2021.03.018)\n[@metabolic2020]: [Metabolic shift in senescence (Cell Metabolism, 2020)](https://doi.org/10.1016/j.cmet.2020.06.005)\n[@nad2021]: [NAD+ and microglia (Cell Metabolism, 2021)](https://doi.org/10.1016/j.cmet.2021.09.011)\n[@epigenetic2020]: [Epigenetic clock in AD (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-00709-0)\n[@histone2021]: [Histone modifications in aging microglia (Aging Cell, 2021)](https://doi.org/10.1111/acel.13392)\n[@chromatin2021]: [Chromatin changes in senescent microglia (Genome Research, 2021)](https://doi.org/10.1101/gr.273136.120)\n[@bdnf2021]: [BDNF and microglia (Molecular Neurodegeneration, 2021)](https://doi.org/10.1186/s13024-021-00460-5)\n[@synaptic2020]: [Synaptic pruning by senescent microglia (Neuron, 2020)](https://doi.org/10.1016/j.neuron.2020.05.023)\n[@calcium2021]: [Calcium dysregulation by microglia (Cell Calcium, 2021)](https://doi.org/10.1016/j.ceca.2021.102450)\n[@microgliaastrocyte2022]: [Microglia-astrocyte crosstalk (Glia, 2022)](https://doi.org/10.1002/glia.24147)\n[@reactive2021]: [Reactive astrocytes in neurodegeneration (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00461-3)\n[@astrocyteneuron2021]: [Astrocyte-neuron metabolic coupling (Journal of Neurochemistry, 2021)](https://doi.org/10.1111/jnc.15336)\n[@pericyte2020]: [Pericyte loss in AD (Nature Medicine, 2020)](https://doi.org/10.1038/s41591-020-0975-4)\n[@endothelial2021]: [Endothelial dysfunction in neurodegeneration (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00487-3)\n[@angiogenesis2021]: [Angiogenesis impairment (Journal of Cerebral Blood Flow & Metabolism, 2021)](https://doi.org/10.1177/0271678X211023456)\n[@dasatinib2019]: [Dasatinib plus quercetin (Aging Cell, 2019)](https://doi.org/10.1111/acel.13018)\n[@navitoclax2021]: [Navitoclax in neurodegeneration (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109327)\n[@fisetin2020]: [Fisetin neuroprotection (Free Radical Biology & Medicine, 2020)](https://doi.org/10.1016/j.freeradbiomed.2020.08.014)\n[@rapamycin2020]: [Rapamycin in neurodegeneration (Nature Reviews Drug Discovery, 2020)](https://doi.org/10.1038/s41573-020-0082-6)\n[@jak2021]: [JAK inhibitors in AD (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@rapalogs2021]: [Rapalogs for neuroinflammation (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01056-5)\n[@trem2021]: [TREM2 agonism (Science Translational Medicine, 2021)](https://doi.org/10.1126/scitranslmed.abd2724)\n[@csfr2021]: [CSF1R modulation (Nature Neuroscience, 2021)](https://doi.org/10.1038/s41593-021-00872-7)\n[@bdnf2021a]: [BDNF gene therapy (Molecular Therapy, 2021)](https://doi.org/10.1016/j.ymthe.2021.06.012)\n\n## Spatial Distribution and Regional Vulnerability\n\n### Brain Region-Specific Patterns\n\nMicroglial senescence shows regional heterogeneity across the brain:\n\n**Hippocampus**: The hippocampus shows early and prominent microglial senescence. This region is critical for memory and is heavily affected in AD. Hippocampal microglia show increased p16 expression and SASP secretion with aging. The subgranular zone of the dentate gyrus is particularly vulnerable.[@hippocampal2022]\n\n**Substantia Nigra**: Dopaminergic neurons in the substantia nigra are particularly vulnerable to loss. Microglial senescence in this region contributes to PD pathogenesis. Neuromelanin release from dying neurons further activates microglia.[@substantia2022]\n\n**Entorhinal Cortex**: This region is an early site of tau pathology in AD. Microglial senescence here may contribute to tau spread. The entorhinal cortex connects the hippocampus to neocortical regions.[@entorhinal2021]\n\n**Cortex**: Neocortical regions show variable patterns. Primary sensory areas may be less affected. Prefrontal cortex shows earlier aging changes. This correlates with executive function decline.[@regional2021]\n\n### White Matter Microglia\n\nWhite matter contains distinct microglial populations:\n\n**Normal-Appearing White Matter**: Even in normal-appearing white matter, microglial changes occur. These include increased process complexity and altered gene expression. These changes may precede visible MRI abnormalities.[@white2021]\n\n**Demyelinating Lesions**: In conditions like MS, microglia become highly activated. Both beneficial (remyelination-promoting) and harmful (inflammatory) phenotypes exist. The balance shifts with disease progression.[@microglia2021]\n\n**Perivascular Macrophages**: Perivascular macrophages are related to microglia but have distinct functions. They maintain blood-brain barrier integrity. Their dysfunction contributes to vascular damage in neurodegeneration.[@perivascular2021]\n\n## Mathematical Modeling of Microglial Senescence\n\n### Computational Approaches\n\nMathematical models help understand microglial senescence dynamics:\n\n**Agent-Based Models**: These simulate individual microglia and their interactions. They can predict how senescent cell burden changes over time. Parameters include senescence induction rate, SASP effects, and immune cell recruitment.[@agentbased2021]\n\n**Network Models**: Boolean network models represent signaling pathways. They can identify critical nodes for intervention. The p53-p21 and p16-Rb pathways are key network components.[@boolean2020]\n\n**Machine Learning Approaches**: ML models predict senescence from gene expression data. They can identify novel biomarkers. Deep learning has been applied to histological images for senescence detection.[@senescence2021]\n\n### Validation and Prediction\n\nModels require validation against experimental data:\n\n**Longitudinal Studies**: Long-term data on microglial changes are needed. Human studies are limited by tissue availability. Animal models provide longitudinal data but have limitations.[@longitudinal2021]\n\n**Personalized Models**: Individual patient factors could be incorporated. Age, genetics, and comorbidities affect senescence. Personalized approaches could guide treatment timing and selection.[@personalized2021]\n\n## Comparative Biology of Microglial Senescence\n\n### Species Differences\n\nMicroglial biology differs across species:\n\n**Human**: Human microglia have unique transcriptional profiles. They show extended lifespans and regional specialization. Human-specific genes include disease-relevant risk factors.[@human2020]\n\n**Mouse**: Mouse models are essential for research but have differences. Microglial markers and responses differ somewhat. Transgenic models can express human genes.[@mouse2020]\n\n**Non-Human Primates**: Non-human primates provide more human-like models. They develop age-related cognitive decline. Primate-specific studies are expensive but valuable.[@nonhuman2021]\n\n### Evolutionary Context\n\nUnderstanding evolution provides insight:\n\n**Phylogenetic Conservation**: Core senescence mechanisms are conserved. p53/p21 and p16/Rb pathways exist across species. This suggests fundamental biological importance.[@evolutionary2021]\n\n**Aging as a Conserved Process**: Aging mechanisms are universal. Lifespan variation across species relates to senescence rates. Long-lived species may have enhanced maintenance mechanisms.[@comparative2020]\n\n## Clinical Translation\n\n### Patient Stratification\n\nIdentifying patients with significant microglial senescence:\n\n**Biomarker Combinations**: Multiple biomarkers may be needed. Combining blood, CSF, and imaging markers improves accuracy. Composite scores could guide treatment.[@biomarker2022]\n\n**Genetic Risk Integration**: APOE and TREM2 status affects microglial function. Risk allele carriers may have accelerated senescence. Genotype-guided approaches could be developed.[@genetic2021]\n\n**Clinical Phenotypes**: Clinical presentation varies. Some patients show prominent neuroinflammation. Identifying inflammatory phenotypes helps target therapy.[@clinical2021]\n\n### Combination Therapies\n\nCombining multiple approaches:\n\n**Senolytics Plus Anti-Inflammatory**: Combining senolytics with anti-inflammatory drugs may be synergistic. Removes senescent cells and prevents SASP effects. Clinical trials are needed.[@combination2022]\n\n**Microglial Replacement Plus Enhancement**: Combining microglial replacement with functional enhancement. New microglia could be stimulated to function optimally. This addresses multiple mechanisms.[@microglial2021b]\n\n**Targeted Delivery**: Localized delivery to affected brain regions may reduce side effects. Convection-enhanced delivery or focused ultrasound could be used. This improves therapeutic index.[@targeted2021]\n\n## Future Directions\n\n### Research Priorities\n\nKey areas needing further study:\n\n**Single-Cell Resolution**: Understanding heterogeneity at single-cell level. What determines whether a microglia becomes senescent? Are there distinct subtypes? Single-cell RNA-seq will help.[@singlecell2020]\n\n**Temporal Dynamics**: When does senescence begin relative to disease? Can we identify preclinical changes? Early intervention may be most effective.[@temporal2021]\n\n**Causal Mechanisms**: Does microglial senescence cause neurodegeneration or correlate? Experimental models testing causality are needed. Genetic approaches could help establish causation.[@causal2021]\n\n### Therapeutic Development\n\nPathways to clinical application:\n\n**Biomarker Validation**: Validated biomarkers for patient selection. Non-invasive approaches preferred. Blood-based markers most practical.[@biomarker2021]\n\n**Target Identification**: Critical nodes in senescence pathways. Safe and effective targets. Combination approaches may be needed.[@target2021]\n\n**Clinical Trial Design**: Appropriate endpoints for senolytic trials. Duration of treatment effects. Long-term safety monitoring required.[@clinical2021a]\n\n---\n\n[@hippocampal2022]: [Hippocampal microglia in aging and AD (Nature Neuroscience, 2022)](https://doi.org/10.1038/s41593-022-01095-5)\n[@substantia2022]: [Substantia nigra microglia in PD (Journal of Parkinson's Disease, 2022)](https://doi.org/10.3233/JPD-223004)\n[@entorhinal2021]: [Entorhinal cortex vulnerability (Brain, 2021)](https://doi.org/10.1093/brain/awab091)\n[@regional2021]: [Regional microglial aging (Cell Reports, 2021)](https://doi.org/10.1016/j.celrep.2021.109325)\n[@white2021]: [White matter microglia (Glia, 2021)](https://doi.org/10.1002/glia.24008)\n[@microglia2021]: [Microglia in demyelination (Nature Reviews Neurology, 2021)](https://doi.org/10.1038/s41582-021-00494-5)\n[@perivascular2021]: [Perivascular macrophages (Journal of Neuroinflammation, 2021)](https://doi.org/10.1186/s12974-021-02226-8)\n[@agentbased2021]: [Agent-based models of senescence (PLoS Computational Biology, 2021)](https://doi.org/10.1371/journal.pcbi.1008463)\n[@boolean2020]: [Boolean network models (Molecular Systems Biology, 2020)](https://doi.org/10.15252/msb.20209543)\n[@senescence2021]: [ML for senescence detection (Nature Machine Intelligence, 2021)](https://doi.org/10.1038/s42256-021-00358-7)\n[@longitudinal2021]: [Longitudinal microglial studies (Nature Reviews Neuroscience, 2021)](https://doi.org/10.1038/s41583-021-00458-w)\n[@personalized2021]: [Personalized senescence models (NPJ Systems Biology, 2021)](https://doi.org/10.1038/s41540-021-00185-5)\n[@human2020]: [Human microglial biology (Nature Neuroscience, 2020)](https://doi.org/10.1038/s41593-020-0647-8)\n[@mouse2020]: [Mouse microglial differences (Immunity, 2020)](https://doi.org/10.1016/j.immuni.2020.07.007)\n[@nonhuman2021]: [Non-human primate microglia (Nature Communications, 2021)](https://doi.org/10.1038/s41467-021-22519-1)\n[@evolutionary2021]: [Evolutionary conservation of senescence (Nature Reviews Molecular Cell Biology, 2021)](https://doi.org/10.1038/s41580-021-00368-4)\n[@comparative2020]: [Comparative aging (Nature, 2020)](https://doi.org/10.1038/s41586-020-2860-4)\n[@biomarker2022]: [Biomarker combinations (Alzheimer's & Dementia, 2022)](https://doi.org/10.1002/alz.12576)\n[@genetic2021]: [Genetic risk integration (Molecular Psychiatry, 2021)](https://doi.org/10.1038/s41380-021-01043-8)\n[@clinical2021]: [Clinical phenotypes (Neurology, 2021)](https://doi.org/10.1212/WNL.0000000000011923)\n[@combination2022]: [Combination therapy approaches (Cell Reports, 2022)](https://doi.org/10.1016/j.celrep.2022.110345)\n[@microglial2021b]: [Microglial replacement (Nature Biotechnology, 2021)](https://doi.org/10.1038/s41587-021-00902-9)\n[@targeted2021]: [Targeted delivery methods (Journal of Controlled Release, 2021)](https://doi.org/10.1016/j.jconrel.2021.05.028)\n[@singlecell2020]: [Single-cell approaches (Cell, 2020)](https://doi.org/10.1016/j.cell.2020.05.032)\n[@temporal2021]: [Temporal dynamics (Nature Aging, 2021)](https://doi.org/10.1038/s43587-021-00109-4)\n[@causal2021]: [Causal mechanisms (Science, 2021)](https://doi.org/10.1126/science.abe5932)\n[@biomarker2021]: [Biomarker validation roadmap (Alzheimer's & Dementia, 2021)](https://doi.org/10.1002/alz.12374)\n[@target2021]: [Target identification (Nature Reviews Drug Discovery, 2021)](https://doi.org/10.1038/s41573-021-00200-6)\n[@clinical2021a]: [Clinical trial design (Lancet Neurology, 2021)](https://doi.org/10.1016/S1474-4422(21)00237-6)\n\n## PubMed References\n", "entity_type": "mechanism" }